<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        171-276-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BENLYSTA 400MG POWDER FOR SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BELIMUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1509.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HOSPIRA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HOSPIRA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA26
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BENLYSTA is a prescription medicine used to treat people with active systemic lupus erythematosus (SLE or lupus) or active lupus nephritis (lupus-related kidney inflammation) who are receiving other lupus medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BENLYSTA contains belimumab which is in a group of medicines called monoclonal antibodies. Lupus is a disease of the immune system (the body system that fights infection). When given together with other medicines for lupus, BENLYSTA decreases lupus disease activity more than other lupus medicines alone.</p><p>&middot;&nbsp; It is not known if BENLYSTA is safe and effective in people with severe active central nervous system lupus.</p><p>&middot;&nbsp; It is not known if BENLYSTA is safe and effective for use in children under 5 years of age when given in a vein (intravenously).</p></td></tr></tbody></table><p>It is not known if BENLYSTA is safe and effective for use in children under 18 years of age when given under the skin (subcutaneously).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>Do not use BENLYSTA if you:</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_e26ded8a-561b-4dc1-b1e8-9493891e4166 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p></td></tr></tbody></table><p>&nbsp;</p><ul><li>are allergic to belimumab or any of the ingredients in BENLYSTA.</li></ul><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>Before you receive BENLYSTA, tell your healthcare provider about all of your medical conditions, including if you:</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_c808ce51-7404-44a5-a6bb-a07c2f8d4855 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><ul><li>think you have an infection or have infections that keep coming back. You should not receive BENLYSTA if you have an infection unless your healthcare provider tells you to.</li><li>have or have had mental health problems such as depression or thoughts of suicide.</li><li>have recently received a vaccination or if you think you may need a vaccination. If you are receiving BENLYSTA, you should not receive live vaccines.</li><li>are allergic to other medicines.</li><li>are receiving other biologic medicines or monoclonal antibodies.</li><li>have or have had any type of cancer.</li><li>are pregnant or plan to become pregnant. It is not known if BENLYSTA will harm your unborn baby. You should talk to your healthcare provider about whether to prevent pregnancy while on BENLYSTA. If you choose to prevent pregnancy, you should use an effective method of birth control while receiving BENLYSTA and for at least 4 months after the final dose of BENLYSTA.</li></ul><p>o&nbsp; Tell your healthcare provider right away if you become pregnant during your treatment with BENLYSTA or if you think you may be pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you become pregnant while receiving BENLYSTA, talk to your healthcare provider about it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. It is not known if BENLYSTA passes into your breast milk. You and your healthcare provider should talk about whether or not you should receive BENLYSTA and breastfeed.</p><p><strong>Tell your healthcare provider about all the medicines you take, </strong>including prescription and over-the-counter medicines, vitamins, and herbal supplements.<!--[if supportFields]><span
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
  "Times New Roman"'><span style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_8af7439e-0ae9-45a5-bb5c-ab07c7c41cf9 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
  "Times New Roman"'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Know the medicines you take. Keep a list of your medicines with you to show to your healthcare provider and pharmacist when you get a new medicine.<!--[if supportFields]><span
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
  "Times New Roman"'><span style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_cdd43d9d-a2bd-4792-bf3a-12cb24a09c7c \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
  "Times New Roman"'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>When </strong><strong>given in a vein </strong><strong>(intravenously)</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_8342ca85-69fb-4094-a2a5-68a960a96b98 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be given BENLYSTA by a healthcare provider through a needle placed in a vein (IV infusion). It takes about 1&nbsp;hour to give you the full dose of BENLYSTA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your healthcare provider will tell you how often you should receive BENLYSTA.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>.&nbsp; &nbsp; &nbsp; Your healthcare provider may give you medicines before you receive BENLYSTA to help reduce your chance of having a reaction. A healthcare provider will watch you closely while you are receiving BENLYSTA and after your infusion for signs of a reaction. A healthcare provider will review the signs and symptoms of possible allergic reactions that could happen after your infusion.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>BENLYSTA can cause serious side effects, including:</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_4940764a-3590-42c5-a693-562cfab7bfa3 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><ul><li><strong>Progressive multifocal leukoencephalopathy (PML). </strong>PML is a serious and life-threatening brain infection. Your chance of getting PML may be higher if you are treated with medicines that weaken your immune system, including BENLYSTA. PML can result in death or severe disability. If you notice any new or worsening medical problems such as those below, tell your healthcare provider right away:</li></ul><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp; memory loss</p><p>o&nbsp;&nbsp; trouble thinking</p><p>o&nbsp;&nbsp; dizziness or loss of balance</p></td><td style="vertical-align:top"><p>o&nbsp; difficulty talking or walking</p><p>o&nbsp; loss of vision</p><p>&nbsp;</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cancer. </strong>BENLYSTA may reduce the activity of your immune system. Medicines that affect the immune system may increase your risk of certain cancers.</p><p>&nbsp;</p><p><strong>The most common side effects of BENLYSTA include:</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
  normal'><span style='font-size:12.0pt;font-family:"Times New Roman",serif;
  mso-fareast-font-family:"Times New Roman"'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_7d1e004b-820c-4e7f-87ff-e729f856f031 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman"'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>o&nbsp;&nbsp; nausea</p><p>o&nbsp;&nbsp; diarrhea</p><p>o&nbsp;&nbsp; fever</p><p>o&nbsp;&nbsp; stuffy or runny nose and sore throat (nasopharyngitis)</p><p>o&nbsp;&nbsp; persistent cough (bronchitis)</p><p>o&nbsp;&nbsp; trouble sleeping (insomnia)</p></td><td style="vertical-align:top"><p>o&nbsp; leg or arm pain</p><p>o&nbsp; depression</p><p>o&nbsp; headache (migraine)</p><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&egrave; <strong>Tell your doctor or a nurse immediately if you get any of these symptoms. </strong></p><p>&egrave; <strong>If you notice any side effects not listed in this leaflet, please tell your doctor.</strong></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Keep BENLYSTA out of the reach and sight of children.</p><p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C)</p><p>Do not freeze.</p><p>Store in the original package to protect from light.</p><p>Do not use BENLYSTA after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.</p></td></tr></tbody></table><p>BENLYSTA should not be disposed of in wastewater or household rubbish. This will help to protect the environment.</p></td></tr></tbody></table><p>BENLYSTA should not be disposed of in wastewater or household rubbish. This will help to protect the environment.</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><u><strong>THE FOLLOWING INFORMATION IS INTENDED FOR MEDICAL OR HEALTHCARE PROFESSIONALS ONLY</strong></u></p><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>Step-by-step instructions </strong><strong>for use and handling &ndash; reconstitution, dilution and administration </strong></p><p><strong>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to reconstitute </strong><strong>BENLYSTA</strong></p><p>BENLYSTA does not contain a preservative; therefore, reconstitution and dilution needs to be carried out under aseptic conditions.<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
  EN-GB;mso-fareast-language:EN-GB;mso-no-proof:yes'><span style='mso-element:
  field-begin'></span> DOCVARIABLE
  vault_nd_7b729523-2607-40b5-a7d4-73da525c949f \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
  "Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
  EN-GB;mso-fareast-language:EN-GB;mso-no-proof:yes'><span style='mso-element:
  field-end'></span></span><![endif]--></p><p>Allow 10-15 minutes for the vial to warm to room temperature.</p><p>It is recommended that a 21-25-gauge needle be used when piercing the vial stopper for reconstitution and dilution.</p><p>The 120&nbsp;mg single-use vial of BENLYSTA is reconstituted with 1.5 mL of sterile Water for Injections to yield a final concentration of 80&nbsp;mg/mL belimumab.</p><p>The 400&nbsp;mg single-use vial of BENLYSTA is reconstituted with 4.8&nbsp;mL of sterile Water for Injections to yield a final concentration of 80&nbsp;mg/mL belimumab.</p><p>The stream of sterile water should be directed toward the side of the vial to minimize foaming. Gently swirl the vial for 60&nbsp;seconds. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 60&nbsp;seconds every 5&nbsp;minutes until the powder is dissolved. <strong>DO NOT SHAKE.</strong></p><p>Reconstitution is typically complete within 10 to 15&nbsp;minutes after the sterile water has been added, but it may take up to 30&nbsp;minutes. Protect the reconstituted solution from direct<strong><em> </em></strong>sunlight.</p><p>If a mechanical reconstitution device is used to reconstitute belimumab it should not exceed 500&nbsp;rpm and the vial should be swirled for no longer than 30&nbsp;minutes.</p><p><strong>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before diluting </strong><strong>BENLYSTA</strong></p><p>Once reconstitution is complete, the solution should be opalescent and colorless to pale yellow, and without particles. Small air bubbles, however, are expected and acceptable.</p><p><strong>3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to dilute the solution for infusion</strong></p><p>The reconstituted product is diluted to 250&nbsp;mL with 0.9% sodium chloride (normal saline), 0.45% sodium chloride (half normal saline), or Lactated Ringer&rsquo;s solution for intravenous infusion. For patients whose body weight is less than or equal to 40 kg, infusion bags with 100 mL normal saline, half normal saline or Lactated Ringer&rsquo;s solution may be considered providing that the resulting belimumab concentration in the infusion bag does not exceed 4 mg/mL.</p><p><strong>5% Dextrose intravenous solutions are incompatible with belimumab and should not be used.&nbsp; </strong></p><p>From a 250&nbsp;mL (or 100 mL) infusion bag or bottle of normal saline, half normal saline, or Lactated Ringer&rsquo;s solution, withdraw and discard a volume equal to the volume of the reconstituted belimumab solution required for the patient&rsquo;s dose.&nbsp; Then add the required volume of the reconstituted belimumab solution into the infusion bag or bottle.&nbsp; Gently invert the bag or bottle to mix the solution. Any unused solution in the vials must be discarded.</p><p>Inspect the belimumab solution visually for particulate matter and discoloration prior to administration. Discard the solution if any particulate matter or discoloration is observed.</p><p>The reconstituted solution, if not used immediately, should be protected from direct sunlight and stored refrigerated at 2&deg;C to 8&deg;C. Solutions diluted in normal saline, half normal saline, or Lactated Ringer&rsquo;s solution may be stored at 2&deg;C to 8&deg;C or room temperature.</p><p>The total time from reconstitution of BENLYSTA to completion of infusion should not</p><p>exceed eight&nbsp;hours.</p><p>&nbsp;</p><p><strong>4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to administer the diluted solution</strong></p><ul><li>BENLYSTA is infused over a 1-hour period.</li><li>BENLYSTA should not be infused concomitantly in the same intravenous line with other agents.</li><li>No incompatibilities between belimumab and polyvinylchloride or polyolefin bags</li><li>have been observed.</li><li>Any unused product or waste material should be disposed of in accordance with local requirements.</li></ul></td></tr></tbody></table><table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>Not all pack sizes may be available in your country.</p><p><strong><em>BENLYSTA</em></strong><strong> </strong>is a trademark owned by or licensed to the GSK group of companies.</p><p>&copy;2023 GSK group of companies. All rights reserved.</p></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>General information about the safe and effective use of BENLYSTA.</strong></p><p>Do not use BENLYSTA for a condition for which it was not prescribed. Do not give BENLYSTA to other people, even if they have the same symptoms that you have. It may harm them.</p><p><strong>W</strong><strong>hat BENLYSTA contains</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:13.0pt;
  mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
  "MS Mincho";mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_0c20a150-717a-40dc-bd27-3c932bc02773 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:13.0pt;
  mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
  "MS Mincho";mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p><p>The active ingredient is belimumab.</p><p>Each 5&nbsp;mL vial contains 120&nbsp;mg belimumab.</p><p>Each 20&nbsp;mL vial contains 400&nbsp;mg belimumab.</p><p>After reconstitution, each mL of solution contains 80 mg belimumab.</p><p><strong>List of Excipients</strong></p><p>Citric acid monohydrate</p><p>Sodium citrate dihydrate</p><p>Sucrose</p><p>Polysorbate 80</p><p>BENLYSTA&nbsp; is dissolved and diluted before being given to you.<br /><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:13.0pt;
  mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
  "MS Mincho";mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-GB'><span
  style='mso-element:field-end'></span></span></b><![endif]--></p></td></tr></tbody></table><p>There is 1 x 20&nbsp;mL vial in each pack.<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:107%;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:AR-SA;
mso-no-proof:yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_936f4978-6851-4a7c-be14-2038ba596e9e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;mso-bidi-font-size:10.0pt;line-height:107%;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:AR-SA;
mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                BENLYSTA is supplied as a white to off-white powder, in a glass vial with a latex-free, siliconized rubber stopper and a flip-off seal.
There is 1 x 5 mL vial in each pack.
There is 1 x 20 mL vial in each pack. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p><strong>Manufactured by: </strong></p><p>GlaxoSmithKline Manufacturing S.p.A*, Parma , Italy</p><p><strong>Marketing Authorization Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia</p><p>*member of GSK group of companies</p><p>&nbsp;</p><p><strong>Version number: US version 2/2023</strong></p><p><strong>Date of issue: &nbsp;15 February 2023</strong></p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><!--[if gte vml 1]><v:rect
   id="AutoShape_x0020_91" o:spid="_x0000_s1026" style='position:absolute;
   margin-left:-4.15pt;margin-top:18pt;width:481.9pt;height:291pt;z-index:251662336;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
   mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokeweight="2.5pt">
   <v:stroke joinstyle="round"/>
   <v:shadow color="#868686"/>
   <w:wrap anchorx="margin"/>
  </v:rect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>To report any side effect(s):</p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance Centre (NPC)</strong></p><ul><li>Reporting Hotline: 19999</li><li>E-mail : npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul><p>&nbsp;</p><p><strong>-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: saudi.safety@gsk.com<u>&nbsp; </u></li><li>Website: https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul></td></tr></tbody></table></td></tr></tbody></table>&nbsp;<p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version number: US version 2/2023
Date of issue: 15 February 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&middot;&nbsp;&nbsp; &quot;بنليستا&quot; هو دواء يُصرف بوصفة طبية، يستخدم لعلاج الأشخاص الذين يعانون من الذئبة الحمامية المجموعية النشطة (مرض الذئبة الحمراء أو الذئبة) &nbsp;او التهاب الكلية الذئبي النشط (التهاب الكلى المرتبط بالذئبة) والذين يتلقون أدوية أخرى لمرض الذئبة.</p><p dir="RTL">&middot;&nbsp;&nbsp; يحتوي &quot;بنليستا&quot; على بيليموماب الذي ينتمي إلى مجموعة من الأدوية تسمى الأجسام المضادة أحادية النسيلة. مرض الذئبة هو مرض يصيب جهاز المناعة (جهاز الجسم الذي يحارب العدوى). عند أخذ &quot;بنليستا&quot; مع أدوية أخرى لمرض الذئبة، فإنه يقلل من نشاط مرض الذئبة أكثر من أدوية الذئبة الأخرى مفردة.</p><p dir="RTL">&middot;&nbsp;&nbsp; من غير المعروف ما إذا كان &quot;بنليستا&quot; آمنًا وفعالاً بالنسبة للأشخاص الذين يعانون من مرض الذئبة النشطة الشديد الذي يصيب الجهاز العصبي المركزي.</p><p dir="RTL">&middot;&nbsp;&nbsp; من غير المعروف ما إذا كان &quot;بنليستا&quot; آمنًا وفعالاً للاستخدام فى الاطفال دون 5&nbsp;سنوات عند اعطائه فى الوريد (وريديا).</p><p dir="RTL">&middot;&nbsp;&nbsp; من غير المعروف ما إذا كان &quot;بنليستا&quot; آمنًا وفعالاً للاستخدام فى الاطفال دون 18&nbsp;سنة عند اعطائه تحت الجلد (تحت جلدياً).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل &quot;بنليستا&quot; إذا كنت:</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-DZ style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span dir=RTL></span><span dir=RTL></span> </span></b><span dir=LTR
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ;mso-bidi-font-weight:
bold'>VAULT_ND_ef5444ba-aa03-49ce-93fc-65fb4c4ebdd0 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-DZ><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-DZ style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من حساسية اتجاه بيليموماب أو أي من مكونات &quot;بنليستا&quot;.</p><p dir="RTL"><strong>قبل أن تتلقى علاج &quot;بنليستا&quot;، أخبر مقدم الرعاية الصحية عن جميع حالاتك المرضيّة، بما في ذلك إذا كنت:</strong><!--[if supportFields]><b><span
lang=AR-DZ style='font-family:"Arial",sans-serif;mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ'><span
style='mso-element:field-begin'></span> </span></b><b><span dir=LTR
style='mso-bidi-language:AR-DZ'>DOCVARIABLE</span></b><span dir=RTL></span><span
dir=RTL></span><b><span style='font-family:"Arial",sans-serif;mso-ascii-font-family:
Calibri;mso-ascii-theme-font:minor-latin;mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span dir=RTL></span><span dir=RTL></span> </span></b><b><span dir=LTR
style='mso-bidi-language:AR-DZ'>VAULT_ND_edd52b3f-4a45-48e0-9ca3-53372d985f2d
\* MERGEFORMAT</span></b><span dir=RTL></span><span dir=RTL></span><b><span
style='font-family:"Arial",sans-serif;mso-ascii-font-family:Calibri;mso-ascii-theme-font:
minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-DZ><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=AR-DZ style='font-family:"Arial",sans-serif;mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;mso-hansi-font-family:Calibri;mso-hansi-theme-font:
minor-latin;mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><s>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </s>تعتقد أنك مصاب بعدوى أو لديك عدوى تستمر بالظهور. يجب ألا تتلقى علاج &quot;بنليستا&quot; إذا كان لديك عدوى ما لم يخبرك مقدم الرعاية الصحية بذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لديك أو كان لديك مشاكل صحية عقلية مثل الاكتئاب أو أفكار الانتحار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تلقيت تطعيمًا مؤخرًا أو إذا كنت تعتقد أنك قد تحتاج إلى تطعيم. إذا كنت تتلقى علاج &quot;بنليستا&quot;، فلا ينبغي أن تتلقى لقاحات حية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لديك حساسية من الأدوية الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تتلقّى أدوية بيولوجية أخرى أو أجسام مضادة أحادية النسيلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; لديك أو كان لديك أي نوع من أنواع السرطان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حاملاً أو تخططين للحمل. من غير المعروف ما إذا كان &quot;بنليستا&quot; سيؤذي جنينكِ. يجب عليكِ التحدث إلى مقدم الرعاية الصحية حول ما إذا كان يجب عليك منع الحمل أثناء استخدام &quot;بنليستا&quot;. إذا اخترتِ منع الحمل، يجب عليكِ استخدام طريقة فعالة للتحكّم بالحمل أثناء تلقيكِ لـ &quot;بنليستا&quot; وأيضًا لمدة 4 أشهر على الأقل من الجرعة النهائية لـ &quot;بنليستا&quot;.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري مقدم الرعاية الصحية على الفور إذا أصبحتِ حاملاً أثناء علاجك بـ &quot;بنليستا&quot; أو إذا كنت تعتقدين أنك حامل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبحتِ حاملاً أثناء تلقيكِ لـ &quot;بنليستا&quot;، فتحدثي إلى مقدم الرعاية الصحية الخاصة بكِ وبطفلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ترضعين طفلك رضاعة طبيعية أو تخططين للإرضاع. من غير المعروف ما إذا كان &quot;بنليستا&quot; ينتقل إلى حليب الأم. يجب أن تتحدثي أنتِ ومقدم الرعاية الصحية عما إذا كان يجب عليك تلقي علاج &quot;بنليستا&quot; مع مواصلة الرضاعة الطبيعية أم لا.</p><p dir="RTL"><strong>أخبر طبيبك عن جميع الأدوية التي تتناولها،</strong> بما فيها الوصفات الطبية والأدوية التي تُصرف دون وصفة طبية، والفيتامينات، والمكمّلات العشبية.</p><p dir="RTL">عليك معرفة الأدوية التي تتناولها. أبقي لائحة الأدوية التي تتناولها برفقتك ليراها طبيبك والصيدلي عند حصولك على دواء جديد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>عند </strong>اعطائه فى الوريد <strong>(وريديًا)</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-DZ style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span dir=RTL></span><span dir=RTL></span> </span></b><span dir=LTR
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ;mso-bidi-font-weight:
bold'>VAULT_ND_ab2f515f-6640-44fb-87dd-8dd0357c2c24 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-DZ><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-DZ style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيعطيك مقدم الرعاية الصحية دواء &quot;بنليستا&quot; باستعمال إبرة موضوعة في الوريد (الحقن داخل الوريد). يستغرق الأمر حوالي ساعة واحدة لإعطائك الجرعة الكاملة من دواء &quot;بنليستا&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيخبرك مقدم الرعاية الصحية بعدد المرات التي يجب أن تتلقى فيها &quot;بنليستا&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يعطيك مقدم الرعاية الصحية بعض الأدوية قبل أن تتلقى &quot;بنليستا&quot; للمساعدة في التقليل من فرص حدوث التفاعلات. سيراقبك مقدّم الرعاية الصحية عن قرب بينما تتلقّى علاج &quot;بنليستا&quot; وبعد الحقن لملاحظة أي علامات للتّفاعلات. سيلاحظ مقدم الرعاية الصحية علامات وأعراض التفاعلات التحسّسية المحتملة التي يمكن أن تحدث بعد الحقن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يمكن أن يسبب &quot;بنليستا&quot; آثارًا جانبية خطيرة، بما في ذلك:</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-DZ style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span dir=RTL></span><span dir=RTL></span> </span></b><span dir=LTR
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ;mso-bidi-font-weight:
bold'>VAULT_ND_01829d3f-711e-414d-858d-bc93e768724b \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-DZ><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-DZ style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p dir="RTL"><strong><s>&nbsp;</s></strong></p><ul><li dir="RTL"><strong>اعتلال بيضاء الدماغ متعدد البؤر المترقي</strong> (<strong>PML</strong>). اعتلال بيضاء الدماغ متعدد البؤر المترقي هو عدوى دماغية خطيرة ومهدّدة للحياة. قد تكون فرصتك في الإصابة باعتلال بيضاء الدماغ متعدد البؤر المترقي أعلى إذا ما تلقّيت علاجًا بأدوية تضعف جهاز المناعة لديك، بما في ذلك &quot;بنليستا&quot;. يمكن أن يؤدي اعتلال بيضاء الدماغ متعدد البؤر المترقي إلى الموت أو الإصابة بعجز شديد. إذا لاحظت أي مشاكل طبية جديدة أو متفاقمة مثل تلك المذكورة أدناه، أخبر مقدم الرعاية الصحية على الفور:</li></ul><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التفكير</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة أو فقدان التوازن</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; صعوبة في الكلام أو المشي</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; فقدان البصر</p><p dir="LTR">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>السرطان.</strong> قد يقلل &quot;بنليستا&quot; من نشاط جهاز المناعة لديك. وقد تزيد الأدوية التي تؤثر على جهاز المناعة من خطر إصابتك ببعض أنواع السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تشمل الآثار الجانبية الأكثر شيوعًا لـ &quot;بنليستا&quot; ما يلي:</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-DZ style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span style='mso-element:field-begin'></span> </span></b><span dir=LTR
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ;mso-bidi-font-weight:
bold'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span dir=RTL></span><span dir=RTL></span> </span></b><span dir=LTR
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ;mso-bidi-font-weight:
bold'>VAULT_ND_8d3f03a2-c7d1-4941-8dbb-6082c5f185e8 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
style='font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-bidi-language:AR-DZ'><span dir=RTL></span><span
dir=RTL></span> <span lang=AR-DZ><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-DZ style='font-family:"Arial",sans-serif;
mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;mso-bidi-language:
AR-DZ'><span style='mso-element:field-end'></span></span></b><![endif]--></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد أو سيلان الأنف والتهاب الحلق (التهاب البلعوم الأنفي)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال مستمر (التهاب الشعب الهوائية)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النوم (الأرق)</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">o&nbsp;&nbsp;&nbsp; ألم في الساق أو الذراع</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; اكتئاب</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; الصداع (الصداع النصفي)</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL"><strong>&ccedil;&nbsp;&nbsp; </strong><strong>أخبر طبيبك أو التمريض على الفور إذا أصابتك أيٌ من هذه الأعراض. </strong></p><p dir="RTL"><strong>&ccedil;&nbsp;&nbsp; </strong><strong>إذا لاحظت ظهور أية أعراض جانبية غير مذكورة بهذه النشرة، فيرجى إخبار الطبيب</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب حفظ دواء بنليستا بعيدًا عن متناول ومرأى الأطفال.</strong></p><p dir="RTL">يُحفظ في الثلاجة (بين 2 درجة مئوية - 8 درجات مئوية)</p><p dir="RTL">يجب عدم تجميده.</p><p dir="RTL">يُحفظ في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">لا تستخدم الدواء بعد تاريخ انتهاء الصلاحية المدوَّن على ملصق الزجاجة وعبوتها الكرتونية. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">يجب عدم التخلص من دواء بنليستا في مياه الصرف أو النفايات المنزلية. فهذا من شأنه أن يساعد في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u><strong>المعلومات التالية خاصة بإخصائيي الرعاية الصحية فقط:</strong></u></p><p dir="RTL"><strong>تعليمات خطوة بخطوة </strong><strong>للاستخدام وكيفية التناول - الاستنشاء والتخفيف والتناول </strong></p><p dir="RTL"><strong>1</strong><strong>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيفية استنشاء بنليستا</strong></p><p dir="RTL">لا يحتوي دواء بنليستا على مواد حافظة، لذا يجب أن يتم الاستنشاء والتخفيف في أجواء معقمة.<!--[if supportFields]><span lang=AR-SA style='font-size:
12.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span style='mso-element:field-begin'></span> </span><span lang=EN-GB
dir=LTR style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
lang=EN-GB style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> </span><span lang=EN-GB
dir=LTR style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'>VAULT_ND_07a67653-7303-4407-95c1-b38b335ccd28 \* MERGEFORMAT</span><span
dir=RTL></span><span dir=RTL></span><span lang=EN-GB style='font-size:12.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> </span><span lang=AR-SA style='font-size:12.0pt;font-family:
"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span style='mso-element:
field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">اترك القنينة في درجة حرارة الغرفة لمدة 10-15 دقيقة حتى تدفأ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوصى باستخدام إبرة بمقياس 21-25 عند ثقب سدادة القنينة للقيام بالاستنشاء والتخفيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم استنشاء قنينة بنليستا 120&nbsp;ملجم أحادية الاستخدام مع 1,5 مل من ماء معقم للحقن، للحصول على تركيز نهائي 80&nbsp;ملجم/مل من بيليموماب.</p><p dir="RTL">يتم استنشاء قنينة بنليستا 400&nbsp;ملجم أحادية الاستخدام مع 4,8&nbsp;مل من ماء معقم للحقن، للحصول على تركيز نهائي 80&nbsp;ملجم/مل من بيليموماب.</p><p dir="RTL">عند ضخ الماء المعقم داخل القنينة، يجب توجيهه إلى جانبها للتقليل من حدوث رغوى. حرّك القنينة برفق بشكل دائري لمدة 60&nbsp;ثانية. اترك القنينة في درجة حرارة الغرفة أثناء الاستنشاء، وحركها دائريًا برفق لمدة 60 ثانية كل 5 دقائق، حتى يذوب المسحوق. <strong>لا تقم بالرج.</strong></p><p dir="RTL"><s>&nbsp;</s></p><p dir="RTL">عادةً ما يكتمل الاستنشاء خلال مدة بين 10 و15&nbsp;دقيقة بعد إضافة الماء المعقم، ولكنه قد يمتد إلى 30 دقيقة. يجب حماية المحلول المستنشأ من أشعة الشمس المباشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة استخدام جهاز استنشاء ميكانيكي لأجل استنشاء بيليموماب، فيجب ألا يتجاوز 500&nbsp;دورة بالدقيقة، ويجب تدوير القنينة لمدة لا تتعدى 30&nbsp;دقيقة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>2</strong><strong>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل تخفيف بنليستا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">فور اكتمال الاستنشاء، يجب أن يظهر المحلول غميمًا وعديم اللون حتى أصفر شاحب، وبلا أية جسيمات. ولكن قد يتوقع وجود فقاعات هوائية صغيرة، وهي أمر مقبول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>3</strong><strong>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيفية تخفيف المحلول للتسريب</strong></p><p dir="RTL">يُخفف المنتج المستنشأ إلى 250&nbsp;مل باستخدام كلوريد صوديوم 0,9٪ (محلول ملحي طبيعي)، أو كلوريد صوديوم 0,45٪ (محلول ملحي نصف طبيعي)، أو محلول رينغر اللاكتاتي للتسريب داخل وريد. بالنسبة للمرضى الذين تبلغ أوزانهم 40 كجم أو أقل، يمكن استخدام أكياس التسريب الوريدي مع 100 مل من المحلول الملحي أو نصف الملحي العادي أو محلول رينغر اللاكتاتي شريطة ألا يتجاوز تركيز بيليموماب الناتج في كيس التسريب الوريدي 4 ملجم/مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتوافق محاليل دكستروز </strong><strong>5</strong><strong>٪ الخاصة بالحقن داخل الوريد مع بيليموماب، ويجب عدم استخدامها.&nbsp; </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">من كيس أو زجاجة تسريب وريدي، تحتوي على 250&nbsp;مل (أو 100 مل) من محلول ملحي طبيعي أو محلول ملحي نصف طبيعي أو محلول رينغر لاكتاتي، قم بسحب وإخراج مقدار من المحلول مساوٍ لحجم محلول بيليموماب المُستنشأ المطلوب لجرعة المريض. ثم أضف المقدار المطلوب من محلول بيليموماب المُستنشأ إلى كيس أو زجاجة التسريب الوريدي. اقلب الكيس أو الزجاجة برفق لمزج المحلول. يجب التخلص من أي محلول متبقي غير مستخدم في القُنينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">افحص محلول بيليموماب ببصرك للتأكد من عدم وجود أية جسيمات ومن عدم تبدل اللون قبل الاستخدام. ويجب التخلص من المحلول في حالة ملاحظة وجود أية جسيمات أو تبدل اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالة عدم استخدام المحلول المُستنشأ على الفور، يجب حمايته من أشعة الشمس المباشرة، وتخزينه في درجة حرارة من 2 درجة مئوية حتى 8 درجات مئوية. وبالنسبة للمحاليل المخففة في محلول ملحي طبيعي أو محلول ملحي نصف طبيعي أو محلول رينغر لاكتاتي، فيمكن تخزينها في درجة حرارة من 2 درجة مئوية حتى 8 درجات مئوية، أو في درجة حرارة الغرفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا يتجاوز الوقت بين استنشاء دواء بنليستا وإتمام التسريب ثماني&nbsp;ساعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>4</strong><strong>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيفية استخدام المحلول المخفف</strong></p><p dir="RTL">يتم عمل تسريب وريدي لمحلول بنليستا لمدة تستغرق ساعة واحدة.</p><p dir="RTL">يجب عدم تسريب بنليستا بالتزامن مع عوامل أخرى في نفس الخط الوريدي.</p><p dir="RTL">لم تتم ملاحظة أية حالات عدم توافق بين بيليموماب والأكياس المصنوعة من البولي أوليفين أو البوليفينيل-كلوريد.</p><p dir="RTL"><s>&nbsp;</s></p><p dir="RTL">ينبغي التخلّص من أي منتج غير مستعمل أو مخلفات دوائية وفق المتطلبات المحلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في بلدك.</p><p dir="RTL"><strong><em>بنليستا</em></strong><em> </em>هي علامة تجارية مملوكة أو مرخصة لمجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&copy; 2023 مجموعة شركات جلاكسوسميث كلاين. جميع الحقوق محفوظة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>معلومات عامة حول الاستخدام الآمن والفعال لـ &quot;بنليستا&quot;.</strong></p><p dir="RTL">لا تستخدم &quot;بنليستا&quot; لحالة لم يوصف لها. لا تعطي &quot;بنليستا&quot; لأشخاص آخرين، حتى وإن كانوا يعانون من نفس الأعراض التي تعاني منها؛ إذ يمكن أن تضرّ بهم.</p><p dir="RTL"><strong>محتويات</strong><strong> بنليستا</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span style='mso-element:
field-begin'></span> </span></b><span lang=EN-GB dir=LTR style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=EN-GB style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><span lang=EN-GB
dir=LTR style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA;mso-bidi-font-weight:bold'>VAULT_ND_645ab5f9-866b-4736-86b3-e999be238379
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span lang=EN-GB style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> </span></b><b style='mso-ansi-font-weight:normal'><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p dir="RTL">المادة الفعالة هي بيليموماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل قنينة 5&nbsp;مل على 120&nbsp;ملجم من بيليموماب.</p><p dir="RTL">تحتوي كل قنينة 20&nbsp;مل على 400&nbsp;ملجم من بيليموماب.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL">بعد مزجه، يحتوي كل 1 مل من المحلول على 80 ملجم من بيليموماب.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>المواد الغير فعالة:</strong></p><p dir="RTL">حمض ستريك أحادي الإماهة</p><p dir="RTL">ثنائي هيدرات سيترات الصوديوم</p><p dir="RTL">سكروز</p><p dir="RTL">البوليسوربات فئة 80</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتم إذابة وتخفيف بنليستا قبل استخدامه.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل بنليستا ومحتويات العبوة</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span style='mso-element:
field-begin'></span> </span></b><span lang=EN-GB dir=LTR style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA;mso-bidi-font-weight:bold'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><b style='mso-ansi-font-weight:normal'><span
lang=EN-GB style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span dir=RTL></span><span dir=RTL></span> </span></b><span lang=EN-GB
dir=LTR style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA;mso-bidi-font-weight:bold'>VAULT_ND_91ff4042-6f5a-40d0-bf83-9a723943319a
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><b
style='mso-ansi-font-weight:normal'><span lang=EN-GB style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span dir=RTL></span><span
dir=RTL></span> </span></b><b style='mso-ansi-font-weight:normal'><span
lang=AR-SA style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"MS Mincho";mso-hansi-theme-font:minor-bidi;
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
AR-SA'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-ansi-font-weight:normal'><span lang=AR-SA style='font-size:13.0pt;
font-family:"Arial",sans-serif;mso-ascii-theme-font:minor-bidi;mso-fareast-font-family:
"MS Mincho";mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:AR-SA'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p dir="RTL">يأتي بنليستا في شكل مسحوق أبيض إلى أبيض مائل إلى الاصفرار، داخل قنينة زجاجية بسدادة مطاطية مصنوعة من السيليكون وخالية من مادة اللاتيكس وغطاء قابل للنزع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توجد قنينة واحدة 5&nbsp;مل في كل عبوة.</p><p dir="RTL">توجد قنينة واحدة 20&nbsp;مل في كل عبوة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع:</strong></p><p dir="RTL">جلاكسوسميث كلاين أس. پي. أيه*. بارما ، إيطاليا</p><p><strong>تسويق: </strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة *، جده، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL">* عضو مجموعة شركات جلاكسوسميث كلاين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>رقم الإصدار: </strong><strong>US Label version 2/2023</strong></p><p dir="RTL"><strong>تاريخ الإصدار: </strong><strong>&nbsp;15 فبراير 2023</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للاستفسار عن أية معلومات عن هذا المستحضر الدوائي، يرجى الاتصال بالأرقام التالية:</strong></p><p dir="RTL">جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><p dir="RTL">هاتف: 6536666 -12-966 +</p><p dir="RTL">جوال: 9882-904-56-966 +</p><p dir="RTL">البريد الإلكتروني : gcc.medinfo@gsk.com</p><p dir="RTL">الموقع الإلكتروني : https://gskpro.com/en-sa/</p><p dir="RTL">ص.ب 55850، جدة 21544، المملكة العربية السعودية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية:</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- المركز الوطني للتيقظ والسلامة الدوائية </strong><strong>(</strong><strong>NPC</strong><strong>)</strong></p><ul><li dir="RTL">الإتصال بالرقم الموحد: 19999</li><li dir="RTL">البريد الإلكتروني: <u>npc.drug@sfda.gov.sa</u></li></ul><ul><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</li></ul><p dir="RTL"><strong>- جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><ul><li dir="RTL">هاتف: 6536666 -12- 966 +</li><li dir="RTL">جوال : 9882-904-56- 966 +</li><li dir="RTL">البريد الإلكتروني : <u>s</u>audi.safety@gsk.com</li><li dir="RTL">الموقع الإلكتروني : <u>https://gskpro.com/en-sa/</u></li><li dir="RTL">ص.ب 55850، جدة 21544، المملكة العربية السعودية.</li></ul><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الإصدار: US Label version 2/2023
تاريخ الإصدار:  15 فبراير 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BENLYSTA 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Belimumab is a human IgG1 monoclonal antibody specific for soluble human B Lymphocyte Stimulator protein (BLyS). Belimumab is produced by recombinant DNA technology in a mammalian cell expression system.

Each vial contains 120 mg or 400 mg belimumab (80 mg/mL after reconstitution).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion

White to off-white powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BENLYSTA (belimumab) is indicated for the treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients aged 5 years and older with active, systemic lupus erythematosus (SLE) who are receiving standard therapy, and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;patients aged 5&nbsp;years and older with active lupus nephritis who are receiving standard therapy.</p><p><strong>Limitations of Use</strong></p><p>The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system (CNS) lupus.. Use of BENLYSTA is not recommended in this situation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Important Administration Information</strong></p><p>BENLYSTA may be administered as an intravenous infusion in patients aged 5 years and older or as a subcutaneous injection in patients aged 18 years and older. Vials are intended for intravenous use only (not for subcutaneous use) and autoinjectors and prefilled syringes are intended for subcutaneous use only (not for intravenous use).</p><p>&nbsp;</p><p>Recommended Intravenous Dosage for Adult and Pediatric Patients with SLE or Lupus Nephritis</p><p><strong>Dosage</strong></p><p>BENLYSTA for intravenous use must be reconstituted and diluted prior to administration. Do not administer as an intravenous push or bolus.</p><p>The recommended intravenous dosage is 10&nbsp;mg/kg at 2‑week intervals for the first 3&nbsp;doses and at 4‑week intervals thereafter. Reconstitute, dilute, and administer as an intravenous infusion over a period of 1 hour. The infusion rate may be slowed or interrupted if the patient develops an infusion reaction. The infusion must be discontinued immediately if the patient experiences a serious hypersensitivity reaction (see<em> Contraindications, Special warnings and precautions for use</em>).</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Precautions Prior to Intravenous Use</strong></p><p>BENLYSTA should be administered by healthcare providers prepared to manage anaphylaxis <em>[</em>see<em> Special warnings and precautions for use, Undesirable effects].</em></p><p>&nbsp;</p><p>Prior to intravenous dosing with BENLYSTA, consider administering premedication for prophylaxis against infusion reactions and hypersensitivity reactions (see<em> Special warnings and precautions for use, Undesirable effects</em>).</p><p><strong>Preparation of Intravenous Solutions</strong></p><p>BENLYSTA for intravenous use is provided as a lyophilized powder in a single‑dose vial and should be reconstituted and diluted by a healthcare professional using aseptic technique as follows. Use of a 21- to 25-gauge needle is recommended when piercing the vial stopper for reconstitution and dilution.</p><p><strong>Reconstitution Instructions for Intravenous Use:</strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Remove the vial of BENLYSTA from the refrigerator and allow to stand for 10 to 15 minutes for the vial to reach room temperature.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Reconstitute the BENLYSTA powder with Sterile Water for Injection, USP, as follows. The reconstituted solution will contain a concentration of 80&nbsp;mg/mL belimumab.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reconstitute the 120-mg vial with 1.5&nbsp;mL Sterile Water for Injection, USP.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reconstitute the 400-mg vial with 4.8&nbsp;mL Sterile Water for Injection, USP.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; The stream of sterile water should be directed toward the side of the vial to minimize foaming. Gently swirl the vial for 60&nbsp;seconds. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 60&nbsp;seconds every 5&nbsp;minutes until the powder is dissolved.<em> Do not shake.</em> Reconstitution is typically complete within 10 to 15&nbsp;minutes after the sterile water has been added, but it may take up to 30&nbsp;minutes. Protect the reconstituted solution from sunlight.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; If a mechanical reconstitution device (swirler) is used to reconstitute BENLYSTA, it should not exceed 500&nbsp;rpm and the vial swirled for no longer than 30&nbsp;minutes.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Once reconstitution is complete, the solution should be opalescent and colorless to pale yellow, and without particles. Small air bubbles, however, are expected and acceptable.</p><p>Dilution Instructions for Intravenous Use:</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp; Dextrose intravenous solutions are incompatible with BENLYSTA. BENLYSTA should only be diluted in 0.9% Sodium Chloride Injection, USP (normal saline), 0.45%&nbsp;Sodium Chloride Injection, USP (half-normal saline), or Lactated Ringer&rsquo;s Injection, USP to a volume of 250&nbsp;mL for intravenous infusion. To prepare the intravenous infusion solution for patients whose body weight is less than or equal to 40&nbsp;kg, a 100 mL bag or bottle of normal saline, half-normal saline, or Lactated Ringer&rsquo;s Injection may be used such that the resulting belimumab concentration in the infusion bag does not exceed 4 mg/mL. From a 250‑mL (or 100‑mL) infusion bag or bottle of normal saline, half-normal saline, or Lactated Ringer&rsquo;s Injection, withdraw and discard a volume equal to the volume of the reconstituted solution of BENLYSTA required for the patient&rsquo;s dose. Then add the required volume of the reconstituted solution of BENLYSTA into the intravenous infusion solution in the infusion bag or bottle. Gently invert the bag or bottle to mix the intravenous infusion solution. Any unused solution in the vials must be discarded.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp; Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard the solution if any particulate matter or discoloration is observed.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp; The reconstituted solution of BENLYSTA, if not used immediately, should be stored protected from direct sunlight and refrigerated at 36&deg;F to 46&deg;F (2&deg;C to 8&deg;C). Solutions of BENLYSTA diluted in normal saline, half-normal saline, or Lactated Ringer&rsquo;s Injection may be stored at 36&deg;F to 46&deg;F (2&deg;C to 8&deg;C) or room temperature. The total time from reconstitution of BENLYSTA to completion of infusion should not exceed 8&nbsp;hours.</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp; No incompatibilities between BENLYSTA and polyvinylchloride or polyolefin bags have been observed.</p><p><strong>Administration Instructions for Intravenous Use</strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; The diluted solution of BENLYSTA should be administered by intravenous infusion over a period of 1&nbsp;hour.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; BENLYSTA should not be infused concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the coadministration of BENLYSTA with other agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BENLYSTA is contraindicated in patients who have had anaphylaxis with belimumab.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Serious Infections</strong></p><p>Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA. Overall, the incidence of serious infections in controlled trials was similar in patients receiving BENLYSTA compared with placebo, whereas fatal infections occurred more frequently in patients receiving BENLYSTA <em>[</em>see<em> Undesirable effects]</em>.</p><p>Consider the risk and benefit before initiating treatment with BENLYSTA in patients with severe or chronic infections. Consider interrupting therapy with BENLYSTA in patients who develop a new infection while receiving it and monitor these patients closely.</p><p><u>Progressive Multifocal Leukoencephalopathy (PML)</u></p><p>Cases of JC virus associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA. Risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function. Consider the diagnosis of PML in any patient presenting with new-onset or deteriorating neurological signs and symptoms and consult with a neurologist or other appropriate specialist as clinically indicated. In patients with confirmed PML, discontinue immunosuppressant therapy, including BENLYSTA.</p><p><strong>Hypersensitivity Reactions, including Anaphylaxis</strong></p><p>Acute hypersensitivity reactions, including anaphylaxis and death, and infusion-related reactions have been reported in association with BENLYSTA <em>[</em>see<em> Undesirable effects]</em>. These events generally occurred within hours of the infusion; however, they may occur later. Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema have been reported and typically occurred up to a week following the most recent infusion. Hypersensitivity, including serious reactions, has occurred in patients who have previously tolerated infusions of BENLYSTA. Limited data suggest that patients with a history of multiple drug allergies or significant hypersensitivity may be at increased risk.</p><p>Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion-related reactions in all cases.<em> </em>In the controlled clinical trials of BENLYSTA administered intravenously in adults with SLE, some patients (13%) received premedication, which may have mitigated or masked a hypersensitivity response or infusion-related reaction; however, there is insufficient evidence to determine whether premedication diminishes the frequency or severity of hypersensitivity reactions or infusion-related reaction.</p><p>BENLYSTA for intravenous use should be administered by healthcare providers prepared to manage anaphylaxis and infusion-related reactions. Healthcare providers should be aware of the risk of hypersensitivity reactions, which may present as infusion-related reactions. In the event of a serious reaction, discontinue BENLYSTA immediately and administer appropriate medical therapy. With intravenous administration, the infusion rate may be slowed or interrupted if the patient develops an infusion reaction. Monitor patients during infusion and for an appropriate period of time after intravenous administration of BENLYSTA. Consider administering premedication as prophylaxis prior to intravenous dosing (see <em>Posology and method of administration</em>).</p><p>Inform patients receiving BENLYSTA of the signs and symptoms of hypersensitivity reactions and instruct them to seek immediate medical care should a reaction occur.</p><p><strong>Depression and Suicidality</strong></p><p>In controlled clinical trials, depression and suicidality were reported in patients receiving BENLYSTA, (see <em>Undesirable effects</em>).</p><p>Assess the risk of depression and suicide considering the patient&rsquo;s medical history and current psychiatric status before treatment with BENLYSTA and continue to monitor patients during treatment. Instruct patients receiving BENLYSTA (and caregivers, if applicable) to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts or behavior, or other mood changes. Consider the risk and benefit of continued treatment with BENLYSTA for patients who develop such symptoms.</p><p><strong>Malignancy</strong></p><p>There is an increased risk of malignancies with the use of immunosuppressants. The impact of treatment with BENLYSTA on the development of malignancies is not known (see <em>Undesirable effects</em>).</p><p>&nbsp;Consider the individual benefit-risk in patients with known risk factors for the development or reoccurrence of malignancy prior to prescribing BENLYSTA. In patients who develop malignancies, consider the risk and benefit of continued treatment with BENLYSTA.</p><p><strong>Immunization</strong></p><p>Because of its mechanism of action, BENLYSTA may interfere with the response to immunizations. Live vaccines should not be given for 30 days before or concurrently with BENLYSTA as clinical safety has not been established. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving BENLYSTA or the effect of BENLYSTA on new immunizations.</p><p><strong>Concomitant Use with Other Biologic Therapies</strong></p><p>&nbsp;Available data do not support the safety and efficacy of concomitant use of BENLYSTA with rituximab in patients with SLE. An increased incidence of serious infections and post-injection systemic reactions in patients receiving BENLYSTA concomitantly with rituximab compared to patients receiving BENLYSTA alone has been observed<em> [</em>see<em> Undesirable effects)]</em>. The safety and efficacy of BENLYSTA concomitantly with other biologic therapies, including B-cell-targeted therapies, have not been established. Caution should be exercised if BENLYSTA is administered in combination with other biologic therapies (see<em> Special warnings and precautions for use</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Formal drug interaction studies have not been performed with BENLYSTA. In clinical trials, BENLYSTA was administered concomitantly with other drugs, including corticosteroids, antimalarials, immunomodulatory and immunosuppressive agents (including azathioprine, cyclophosphamide, methotrexate, and mycophenolate), angiotensin pathway antihypertensives, HMG‑CoA reductase inhibitors (statins), and/or non-steroidal anti-inflammatory drugs (NSAIDs) without evidence of a clinically meaningful effect of these concomitant medications on belimumab pharmacokinetics. The effect of belimumab on the pharmacokinetics of other drugs has not been evaluated (see<em> Pharmacological properties</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p><u>Risk Summary</u></p><p>Available data on use of BENLYSTA in pregnant women, from observational studies, published case reports, and post-marketing surveillance, are insufficient to determine whether there is a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with SLE (see<em> Clinical Considerations</em>). Monoclonal antibodies, such as belimumab, are actively transported across the placenta during the third trimester of pregnancy and may affect immune response in the in utero-exposed infant (see<em> Clinical Considerations</em>). In an animal combined embryo-fetal and pre- and post-natal development study with monkeys that received belimumab by intravenous administration, there was no evidence of fetal harm with exposures approximately 9&nbsp;times (based on intravenous administration) and 20&nbsp;times (based on subcutaneous administration) the exposure at the maximum recommended human dose (MRHD). Belimumab-related findings in monkey fetuses and/or infants included reductions of B-cell counts, reductions in the density of lymphoid tissue B-lymphocytes in the spleen and lymph nodes, and altered IgG and IgM titers. The no-adverse-effect-level (NOAEL) was not identified for these findings; however, they were reversible within 3 to 12&nbsp;months after the drug was discontinued<em> (see Data)</em>. Based on animal data and the mechanism of action of belimumab, the immune system in infants of treated mothers may be adversely affected. It is unknown, based on available data, whether immune effects, if identified, are reversible. (see<em> Pharmacological properties</em>).</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p><p><u>Clinical Considerations</u></p><p><em>Disease-Associated Maternal and/or Embryo/Fetal Risk:</em> Pregnant women with SLE are at increased risk of adverse pregnancy outcomes, including worsening of the underlying disease, premature birth, miscarriage, and intrauterine growth restriction. Maternal lupus nephritis increases the risk of hypertension and preeclampsia/eclampsia. Passage of maternal autoantibodies across the placenta may result in adverse neonatal outcomes, including neonatal lupus and congenital heart block.</p><p><em>Fetal/Neonatal Adverse Reactions:</em> Monoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to BENLYSTA in utero. Monitor an infant of a treated mother for B-cell reduction and other immune dysfunction (see<em> Special warnings and precautions for use</em>).</p><p><u>Data</u></p><p><em>Animal Data:</em> In a combined embryo-fetal and pre- and post-natal development study, pregnant cynomolgus monkeys received belimumab at intravenous doses of 0, 5, or 150&nbsp;mg/kg every 2 weeks from confirmation of pregnancy at Gestation Days (GD) 20 to 22, throughout the period of organogenesis (up to approximately GD 50), and continuing to either the day of scheduled cesarean section (GD&nbsp;150 [late third trimester]) or the day of parturition. There was no evidence of maternal toxicity, effects on embryofetal and infant survival, or structural abnormalities at exposure approximately 9&nbsp;times the MRHD of 10&nbsp;mg/kg intravenously or 20&nbsp;times the MRHD of 200&nbsp;mg subcutaneously (on an AUC basis with maternal animal intravenous doses up to 150&nbsp;mg/kg). Belimumab-related findings in mothers included reductions of immature and mature B-cell counts and in fetuses and/or infants included reductions of immature and mature B-cell counts, reductions in the density of lymphoid tissue B-lymphocytes in the spleen and lymph nodes, reduced spleen weights, increased IgG titers, and reduced IgM titers. B-cell counts in infant monkeys exposed to belimumab in utero recovered by 3&nbsp;months of age and in mothers after 1&nbsp;year. IgG and IgM levels in infant monkeys recovered by 6&nbsp;months of age and the reductions in B-lymphocytes in the lymph nodes and spleen were reversed by 1&nbsp;year of age. Belimumab crossed the placenta, as it was detected in fetal cord blood and amniotic fluid on GD&nbsp;150.</p><p><strong>Lactation</strong></p><p><u>Risk Summary</u></p><p>No information is available on the presence of belimumab in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Belimumab was detected in the milk of cynomolgus monkeys; however, due to species-specific differences in lactation physiology, animal data may not predict drug levels in human milk. Maternal IgG is known to be present in human milk. If belimumab is transferred into human milk, the effects of local exposure in the gastrointestinal tract and potential limited systemic exposure in the infant to belimumab are unknown. The lack of clinical data during lactation precludes clear determination of the risk of BENLYSTA to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for BENLYSTA, and any potential adverse effects on the breastfed child from BENLYSTA or from the underlying maternal condition.</p><p><strong>Contraception in males and females </strong></p><p>Following an assessment of benefit versus risk, if prevention of pregnancy is warranted, females of reproductive potential should use effective contraception during treatment and for at least 4&nbsp;months after the final treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no studies to investigate the effect of <em>BENLYSTA</em> on driving performance or the ability to operate machinery.&nbsp; No detrimental effects on such activities are predicted from the pharmacology of <em>BENLYSTA</em>.&nbsp;&nbsp;</p><p>The clinical status of the patient and the safety profile of <em>BENLYSTA</em> should be borne in mind when considering the patient&#39;s ability to perform tasks that require judgement, motor or cognitive skills<strong><em>.</em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8.1 Adverse </strong><strong>Reactions</strong></p><p>The following serious adverse reactions are described below in the Special warnings and precautions for use section:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious Infections (see<em> Special warnings and precautions for use</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity Reactions, including Anaphylaxis (see<em> Special warnings and precautions for use</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression and Suicidality (see<em> Special warnings and precautions for use</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malignancy (see<em> Special warnings and precautions for use</em>).</p><p><strong>4.8.2 Clinical Trials Experience</strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>Clinical Trials with Intravenous Administration in Adult and Pediatric Patients</p><p><em>Adult Patients with SLE:</em> The data described in Table&nbsp;1 reflect exposure to BENLYSTA administered intravenously plus standard therapy compared with placebo plus standard therapy in 2,133 adult patients with SLE in 3&nbsp;controlled trials (Trials 1, 2, and 3). Patients received BENLYSTA plus standard therapy at doses of 1 mg/kg (n&nbsp;=&nbsp;673), 4&nbsp;mg/kg (n&nbsp;=&nbsp;111; Trial 1 only), or 10&nbsp;mg/kg (n&nbsp;=&nbsp;674), or placebo plus standard therapy (n&nbsp;=&nbsp;675) intravenously over a 1‑hour period on Days&nbsp;0, 14, 28, and then every 28&nbsp;days. In 2 of the trials (Trial 1 and Trial 3), treatment was given for 48&nbsp;weeks, while in the other trial (Trial 2) treatment was given for 72&nbsp;weeks (see<em> Clinical Studies</em>). Because there was no apparent dose-related increase in the majority of adverse events observed with BENLYSTA, the safety data summarized below are presented for the 3 intravenous doses pooled, unless otherwise indicated; the adverse reaction table displays the results for the recommended intravenous dose of 10 mg/kg compared with placebo.</p><p>In these trials, 93% of patients treated with BENLYSTA plus standard therapy reported an adverse event compared with 92% treated with placebo plus standard therapy.</p><p>The most common serious adverse events were serious infections (6% and 5.2% in the groups receiving BENLYSTA and placebo plus standard therapy, respectively), some of which were fatal</p><p>The most commonly reported adverse events, occurring in &sup3;5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.</p><p>The proportion of patients who discontinued treatment due to any adverse reaction during the controlled clinical trials was 6.2% for patients receiving BENLYSTA plus standard therapy and 7.1% for patients receiving placebo plus standard therapy. The most common adverse reactions resulting in discontinuation of treatment (&ge;1% of patients receiving BENLYSTA or placebo) were infusion reactions (1.6% BENLYSTA and 0.9% placebo), lupus nephritis (0.7% BENLYSTA and 1.2% placebo), and infections (0.7% BENLYSTA and 1% placebo).</p><p>Table&nbsp;1 lists adverse reactions, regardless of causality, occurring in at least 3% of patients with SLE who received BENLYSTA 10 mg/kg plus standard therapy and at an incidence at least 1% greater than that observed with placebo plus standard therapy in 3 controlled trials (Trials 1, 2, and 3).</p><p>Table&nbsp;1. Incidence of Adverse Reactions Occurring in at Least 3% of Adult Patients with SLE Treated with BENLYSTA 10&nbsp;mg/kg plus Standard Therapy and at Least 1% More Frequently than in Patients Receiving Placebo plus Standard Therapy</p><table border="1" cellspacing="0" cellpadding="0" style="width:613px"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:bottom"><p><strong>BENLYSTA</strong></p><p><strong>10&nbsp;mg/kg + </strong></p><p><strong>Standard Therapy</strong></p><p><strong>(n&nbsp;=&nbsp;674)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Placebo +</strong></p><p><strong>Standard Therapy</strong></p><p><strong>(n&nbsp;=&nbsp;675)</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Migraine</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Cystitis</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis viral</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>1</p></td></tr></tbody></table><p>Infections: In the controlled clinical trials of BENLYSTA administered intravenously in adults with SLE, the overall incidence of infections was 71% in patients receiving BENLYSTA compared with 67% in patients receiving placebo. The most frequent infections (&gt;5% of patients receiving BENLYSTA) were upper respiratory tract infection, urinary tract infection, nasopharyngitis, sinusitis, bronchitis, and influenza. Infections leading to discontinuation of treatment occurred in 0.7% of patients receiving BENLYSTA and 1.0% of patients receiving placebo.</p><p>In a randomized, double-blind, placebo-controlled, 104-week trial of active lupus nephritis in adults receiving BENLYSTA administered intravenously (N&nbsp;=&nbsp;448), the overall incidence of infections was 82% in patients receiving BENLYSTA compared with 76% in patients receiving placebo. Serious Infections: In controlled trials of BENLYSTA administered intravenously in adults with SLE, the incidence of serious infections was 6.0% in patients receiving BENLYSTA and 5.2% in patients receiving placebo. The most frequent serious infections included pneumonia, urinary tract infections, cellulitis, and bronchitis. Fatal infections occurred in 0.3% (4/1,458) of patients receiving BENLYSTA and in 0.1% (1/675) of patients receiving placebo.</p><p>In a randomized, double-blind, placebo-controlled, 104-week trial of active lupus nephritis in adults receiving BENLYSTA administered intravenously, serious infections occurred in 14% of patients receiving BENLYSTA and in 17% of patients receiving placebo. Fatal infections occurred in 0.9% (2/224) of patients receiving BENLYSTA and in 0.9% (2/224) of patients receiving placebo.</p><p>In a randomized, double-blind, placebo-controlled, 52-week, post marketing safety trial of BENLYSTA administered intravenously in adults with SLE (N&nbsp;=&nbsp;4,003), the incidence of serious infections was 3.7% in patients receiving BENLYSTA compared with 4.1% in patients receiving placebo. Serious infections leading to discontinuation of treatment occurred in 1.0% of patients receiving BENLYSTA and in 0.9% of patients receiving placebo. Fatal infections occurred in 0.45% (9/2,002) of patients receiving BENLYSTA and in 0.15% (3/2,001) of patients receiving placebo, where the incidence of all-cause mortality was 0.50% (10/2,002) in patients receiving BENLYSTA and 0.40% (8/2,001) in patients receiving placebo.</p><p>Hypersensitivity Reactions, including Anaphylaxis: In the controlled clinical trials of BENLYSTA administered intravenously in adults with SLE, hypersensitivity reactions (occurring on the same day of infusion) were reported in 13% (191/1,458) of patients receiving BENLYSTA and 11% (76/675) of patients receiving placebo. Anaphylaxis was observed in 0.6% (9/1,458) of patients receiving BENLYSTA and 0.4% (3/675) of patients receiving placebo. Manifestations included hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea.</p><p>Infusion-Related Reactions: In the controlled clinical trials of BENLYSTA administered intravenously in adults with SLE, adverse events associated with the infusion (occurring on the same day of the infusion) were reported in 17% (251/1,458) of patients receiving BENLYSTA and 15% (99/675) of patients receiving placebo. Serious infusion reactions (excluding hypersensitivity reactions) were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included bradycardia, myalgia, headache, rash, urticaria, and hypotension. The most common infusion reactions (&ge;3% of patients receiving BENLYSTA) were headache, nausea, and skin reactions.</p><p>&nbsp;</p><p>Depression and Suicidality: In controlled clinical trials of BENLYSTA administered intravenously in adults with SLE (N&nbsp;=&nbsp;2,133), psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), primarily related to depression-related events (6.3% BENLYSTA; 4.7% placebo), insomnia (6% BENLYSTA; 5.3% placebo), and anxiety (3.9% BENLYSTA; 2.8% placebo). Serious psychiatric events were reported in 0.8% (12/1,458) of patients receiving BENLYSTA and 0.4% (3/675) of patients receiving placebo. Serious depression was reported in 0.4% (6/1,458) of patients receiving BENLYSTA and 0.1% (1/675) of patients receiving placebo. Two suicides (0.1%) were reported in patients receiving BENLYSTA (one with 10&nbsp;mg/kg and one with 1&nbsp;mg/kg).</p><p>In a randomized, double-blind, placebo-controlled, 52-week, post marketing safety trial of BENLYSTA administered intravenously in adults with SLE (N&nbsp;=&nbsp;4,003), serious psychiatric events were reported in 1% (20/2,002) of patients receiving BENLYSTA and 0.3% (6/2,001) of patients receiving placebo. Serious depression was reported in 0.3% (7/2,002) of patients receiving BENLYSTA and in &lt;0.1% (1/2,001) receiving placebo. The overall incidence of serious suicidal ideation or behavior or self-injury without suicidal intent was 0.7% (15/2,002) of patients receiving BENLYSTA and 0.2% (5/2,001) of patients receiving placebo. On the Columbia-Suicide Severity Rating Scale (C-SSRS), 2.4% (48/1,974) of patients receiving BENLYSTA reported suicidal ideation or behavior compared with 2% (39/1,988) of patients receiving placebo. No suicide was reported in either group.</p><p>The intravenous trials above did not exclude patients with a history of psychiatric disorders.</p><p>Malignancy: In the controlled clinical trials of BENLYSTA administered intravenously in adults with SLE, malignancies (including non-melanoma skin cancers) were reported in 0.4% of patients receiving BENLYSTA and 0.4% of patients receiving placebo. In the intravenous controlled clinical trials, malignancies, excluding non-melanoma skin cancers, were observed in 0.2% (3/1,458) and 0.3% (2/675) of patients receiving BENLYSTA and placebo, respectively.Black/African-American Patients: The safety of BENLYSTA 10&nbsp;mg/kg administered intravenously plus standard therapy (n&nbsp;=&nbsp;331) compared with placebo plus standard therapy (n&nbsp;=&nbsp;165) in Black patients with SLE (Trial&nbsp;4) was consistent with the known safety profile of BENLYSTA administered intravenously plus standard therapy in the overall population (see<em> Clinical Studies</em>).</p><p>Adult Patients with Lupus Nephritis: The safety of BENLYSTA 10&nbsp;mg/kg administered intravenously plus standard therapy (n&nbsp;=&nbsp;224) compared with placebo plus standard therapy (n&nbsp;=&nbsp;224) was evaluated in adults with active lupus nephritis for up to 104&nbsp;weeks (Trial&nbsp;5<em>) </em>(see<em> Clinical Studies</em>). The adverse reactions observed were consistent with the known safety profile of BENLYSTA administered intravenously plus standard therapy in patients with SLE. Cases of myelosuppression, including febrile neutropenia, leukopenia, and pancytopenia, were observed in subjects who received induction therapy with cyclophosphamide followed by maintenance therapy with azathioprine, or mycophenolate.</p><p><strong>Pediatric Patients</strong></p><p>The safety of BENLYSTA administered intravenously plus standard therapy (n&nbsp;=&nbsp;53) compared with placebo plus standard therapy (n&nbsp;=&nbsp;40) was evaluated in 93&nbsp;pediatric patients with SLE (Trial&nbsp;6). The adverse reactions observed were consistent with those observed in adults with SLE (see<em> Clinical Studies</em>).</p><p>&nbsp;</p><p>Concomitant Use of Rituximab in Adults: BENLYSTA administered subcutaneously in combination with rituximab was studied in a Phase&nbsp;III, randomized, double-blind, placebo-controlled, 104-week study in adult patients with SLE. Patients were randomized to 1 of the 3 treatment arms: BENLYSTA with a single cycle of rituximab (n&nbsp;=&nbsp;144); BENLYSTA with placebo (n&nbsp;=&nbsp;72); BENLYSTA plus standard therapy (n&nbsp;=&nbsp;76). In general, adverse reactions were consistent with the known safety profile of BENLYSTA and rituximab. When compared with BENLYSTA and placebo or BENLYSTA plus standard therapy, BENLYSTA in combination with rituximab was associated with higher frequency of serious adverse events (13.9%, 19.7%, 22.2%), serious infections (2.8%, 5.3%, 9.0%), and post-injection systemic reactions (9.7%, 5.3%, 13.2%).</p><p><strong>&nbsp;</strong></p><p><strong>4.8.3 Postmarketing Experience</strong></p><p>The following adverse reactions have been identified during postapproval use of BENLYSTA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatal anaphylaxis <em>[see </em><em>Special </em><em>Warnings and Precautions for use</em><em>].</em></p><p><strong>&nbsp;</strong></p><p><strong><em>Use in Specific Populations</em></strong></p><p><strong>Pediatric Use</strong></p><p>Safety and effectiveness of BENLYSTA have been established for the treatment of SLE and lupus nephritis in pediatric patients 5 to 17&nbsp;years old.</p><p>Use of BENLYSTA in pediatric patients with SLE is supported by evidence from pharmacokinetic (PK) and efficacy results from a pediatric study (Trial 6), as well as PK exposure and extrapolation of the established efficacy of BENYLSTA plus standard therapy from the Phase 3 intravenous studies in adults with SLE. A randomized, double blind, placebo controlled, PK, efficacy, and safety study (Trial 6) to evaluate intravenously administered BENLYSTA 10 mg/kg plus standard therapy compared with placebo plus standard therapy over 52 weeks was conducted in 93 pediatric patients with SLE. The proportion of pediatric patients achieving an SRI-4 response was higher in patients receiving BENLYSTA plus standard therapy compared with placebo plus standard therapy. Pediatric patients receiving BENLYSTA plus standard therapy also had a lower risk of experiencing a severe flare compared with placebo plus standard therapy (see Clinical Studies). Pharmacokinetics were evaluated in a total of 53&nbsp;pediatric patients with SLE and were consistent with the adult population with SLE <em>[see Pharmacokinetic properties]</em>.</p><p>Use of BENLYSTA in pediatric patients with active lupus nephritis is based on the extrapolation of efficacy from the intravenous study in adults (n&nbsp;=&nbsp;224) with active lupus nephritis, and supported by pharmacokinetic data from intravenous studies in adults (n&nbsp;=&nbsp;224) with active lupus nephritis and from pediatric patients (n&nbsp;=&nbsp;53) with SLE. Estimated belimumab exposures for pediatric patients were comparable to adults with active lupus nephritis <em>[see Pharmacokinetic properties]</em>.</p><p>The safety and effectiveness of intravenous administration of BENLYSTA have not been established in pediatric patients younger than 5 years of age.</p><p>The safety and effectiveness of subcutaneous administration of BENLYSTA have not been established in pediatric patients younger than 18 years of age.</p><p><strong>Geriatric Use</strong></p><p>Clinical studies of BENLYSTA did not include sufficient numbers of subjects aged 65 or older to determine whether they respond differently from younger subjects. Use with caution in geriatric patients.</p><p><strong>Renal Impairment</strong></p><p>The safety and efficacy of BENLYSTA were evaluated in studies that included patients with SLE who had mild (creatinine clearance [CrCl] &sup3;60 and &lt;90&nbsp;mL/min), moderate (CrCl &sup3;30 and &lt;60&nbsp;mL/min), or severe (CrCl &sup3;15 and &lt;30&nbsp;mL/min) renal impairment. No dosage adjustment is recommended in patients with renal impairment.</p><p><strong>Hepatic Impairment</strong></p><p>No formal trials were conducted to examine the effects of hepatic impairment on the pharmacokinetics of belimumab. No dosage adjustment is recommended in patients with hepatic impairment.</p><p><strong>Racial Groups</strong></p><p>In Trial 2 and Trial 3 (intravenous dosing), SLE Responder Index-4 (SRI-4) response rates were lower for Black patients receiving BENLYSTA plus standard therapy relative to Black patients receiving placebo plus standard therapy (see Clinical Studies).</p><p>In Trial 4 (intravenous dosing), a 2:1 randomized, placebo-controlled trial in Black patients, SLE Responder Index (SRI-S2K) response rates were higher for Black patients receiving BENLYSTA plus standard therapy (49%) relative to Black patients receiving placebo plus standard therapy (42%). However, the treatment difference was not statistically significant (see Clinical Studies).</p><p>In Trial 7 (subcutaneous dosing), SRI-4 response was 45% (26/58) in Black patients receiving BENLYSTA plus standard therapy compared with 39% (13/33) in Black patients receiving placebo plus standard therapy (see Clinical Studies).</p><p>The safety profile of BENLYSTA in Black patients was consistent with the known safety profile of BENLYSTA administered in the overall population (see Undesirable effects).</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting Hotline: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>GSK- Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: <u>s</u>audi.safety@gsk.com<u>&nbsp; </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK- Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited experience with overdosage of belimumab. Adverse reactions reported in association with cases of overdose have been consistent with those expected for belimumab.</p><p>Two doses of up to 20&nbsp;mg/kg have been given intravenously to humans with no increase in incidence or severity of adverse reactions compared with doses of 1, 4, or 10&nbsp;mg/kg.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ATC Code</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=FR style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"MS Mincho";mso-bidi-font-family:"Times New Roman";mso-ansi-language:FR;
layout-grid-mode:line'><span style='mso-element:field-begin'></span></span></b><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:"MS Mincho";
mso-bidi-font-family:"Times New Roman";layout-grid-mode:line'> DOCVARIABLE
vault_nd_ce01b2a1-6687-47dc-b9ad-b1a1e84022c2 \* MERGEFORMAT </span></b><b
style='mso-bidi-font-weight:normal'><span lang=FR style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"MS Mincho";mso-bidi-font-family:"Times New Roman";mso-ansi-language:FR;
layout-grid-mode:line'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=FR style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"MS Mincho";mso-bidi-font-family:"Times New Roman";mso-ansi-language:FR;
layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>L04AA26</p><p><strong>Mechanism of Action</strong></p><p>BENLYSTA is a BLyS-specific inhibitor that blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B&nbsp;cells. BENLYSTA does not bind B cells directly, but by binding BLyS, BENLYSTA inhibits the survival of B cells, including autoreactive B&nbsp;cells, and reduces the differentiation of B&nbsp;cells into immunoglobulin-producing plasma cells.</p><p><strong>Pharmacodynamic Effect</strong></p><p>Treatment with BENLYSTA in adult patients significantly reduced circulating CD19+, CD20+, na&iuml;ve, and activated B&nbsp;cells, and the SLE B‑cell subset at Week&nbsp;52. Reductions in na&iuml;ve and the SLE B‑cell subset were observed as early as Week&nbsp;8 and sustained to Week&nbsp;52. Memory cells increased initially and slowly declined toward baseline levels by Week&nbsp;52.</p><p>Treatment with BENLYSTA in adult patients led to reductions in IgG and anti-double-stranded DNA antibodies (anti-dsDNA) which were observed as early as Week&nbsp;8 and sustained through Week&nbsp;52. In patients with low complement levels at baseline, treatment led to increases in complement C3 and C4 as early as Week&nbsp;12 and were sustained through Week&nbsp;52.</p><p>The pharmacodynamic response observed in Black patients (Trial&nbsp;4) was consistent with the previous studies.</p><p>In patients with active lupus nephritis (Trial&nbsp;5), following treatment with BENLYSTA, there was a decrease in serum IgG as early as Week&nbsp;4, and subsequently there was an increase in serum IgG levels which was associated with decreased proteinuria. Reductions in autoantibodies, increases in complement, and reductions in circulating total B&nbsp;cells and B‑cell subsets observed were consistent with the SLE studies.</p><p>In Trial&nbsp;6 (pediatric dosing), the pharmacodynamic response was consistent with the adult data.</p><p>The clinical relevance of above mentioned pharmacodynamic biomarkers has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intravenous Infusion in Adults</p><p>Systemic Lupus Erythematosus: The pharmacokinetic parameters displayed in Table&nbsp;2 are based on population parameter estimates from 563&nbsp;adult patients who received BENLYSTA 10&nbsp;mg/kg<em>.</em></p><p>Table&nbsp;2. Population Pharmacokinetic Parameters in Adult Patients with SLE after Intravenous Infusion of BENLYSTA 10 mg/kg<sup>a</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><strong>Pharmacokinetic Parameter</strong></p></td><td style="vertical-align:bottom"><p><strong>Population Estimates</strong></p><p><strong>(n&nbsp;=&nbsp;563)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Peak concentration (C<sub>max</sub>, mcg/mL)</p></td><td style="vertical-align:top"><p>313</p></td></tr><tr><td style="vertical-align:top"><p>Area under the curve (AUC<sub>0-</sub><sub>&yen;</sub>, day●mcg/mL)</p></td><td style="vertical-align:top"><p>3,083</p></td></tr><tr><td style="vertical-align:top"><p>Distribution half-life (t<sub>&frac12;</sub>, days)</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top"><p>Terminal half-life (t<sub>&frac12;</sub>, days)</p></td><td style="vertical-align:top"><p>19.4</p></td></tr><tr><td style="vertical-align:top"><p>Systemic clearance (CL, mL/day)</p></td><td style="vertical-align:top"><p>215</p></td></tr><tr><td style="vertical-align:top"><p>Volume of distribution (Vss, L)</p></td><td style="vertical-align:top"><p>5</p></td></tr></tbody></table><p><sup>a</sup> Intravenous infusions were administered at 2‑week intervals for the first 3&nbsp;doses and at 4‑week intervals thereafter.</p><p>Lupus Nephritis: A population pharmacokinetic analysis was conducted in 224 adult patients with lupus nephritis who received belimumab 10&nbsp;mg/kg intravenously (Days 0, 14, 28, and then every 28 days up to 104 weeks) plus standard therapy (see<em> Clinical Studies</em>)<em> </em>In patients with lupus nephritis, due to additional clearance associated with proteinuria, belimumab exposure was initially lower than observed in SLE studies and lower belimumab exposure was observed in patients with higher proteinuria. When the proteinuria was decreased to approximately &le;1&nbsp;g/g after treatment, belimumab clearance and exposure were similar to that observed in patients with SLE who received belimumab 10&nbsp;mg/kg intravenously. The available data do not support a dose adjustment in patients with high proteinuria.</p><p>Specific Populations</p><p>The following information is based on the population pharmacokinetic analyses of intravenous administration and subcutaneous administration of BENLYSTA.</p><p>Age: Age did not significantly influence the pharmacokinetics of belimumab, where the majority of subjects were between 18 and 45&nbsp;years (70% with intravenous dosing; 74% with subcutaneous dosing).</p><p><em>Geriatric Patients</em>: Limited pharmacokinetic data are available for elderly patients as less than 2% of the subjects included in the pharmacokinetic analysis were 65&nbsp;years or older (see<em> Use in Specific Populations</em>).</p><p><em>Pediatric Patients</em>: The pharmacokinetic parameters are based on individual parameter of belimumab estimates from a population pharmacokinetic analysis of 53 pediatric patients with SLE (Trial&nbsp;6). Following IV administration of 10&nbsp;mg/kg on Days 0, 14, and 28, and at 4‑week intervals thereafter, belimumab exposures were similar between pediatric and adult subjects with SLE. Steady-state geometric mean C<sub>max</sub>, C<sub>min</sub>, C<sub>avg</sub>, and AUC values were 305, 42, 92&nbsp;mcg/mL, and 2,569 day&middot;mcg/mL in the 5- to 11-year-old group, and 317, 52, 112&nbsp;mcg/mL and 3,126 day&middot;mcg/mL in the 12- to 17-year-old group. (See<em> Use in Specific Populations</em>).</p><p>For active lupus nephritis, the pharmacokinetics of belimumab in pediatric patients were estimated based on a population pharmacokinetic model developed from 224&nbsp;adults with active lupus nephritis and validated using data from 53&nbsp;pediatric patients with SLE. With IV administration of 10&nbsp;mg/kg on Days 0, 14 and 28 and at 4-week intervals thereafter, the simulated belimumab exposures for both the 5- to 11-year-old group and the 12- to 17-year-old group were estimated to be comparable to adults with active lupus nephritis (See<em> Use in Specific Populations</em>).</p><p>Male and Female Patients: Gender did not significantly influence belimumab pharmacokinetics in the largely female trial population (94% with intravenous dosing; 85% with subcutaneous dosing).</p><p>Racial Groups: Race did not significantly influence belimumab pharmacokinetics. The racial distribution with intravenous administration was 53% White, 16% Asian, 16% Alaska native/American Indian, and 14% Black in Trials&nbsp;1, 2, and 3. Trial&nbsp;4 enrolled only Black patients. The racial distribution with subcutaneous administration (Trial&nbsp;7) was 61% White, 20% Asian, 11% Black, and 6% Alaska native/American Indian.</p><p>Weight: Body weight and body mass index (BMI) had no clinically relevant effect on the pharmacokinetics of belimumab administered subcutaneously in adults. No dose adjustment is recommended based on weight or BMI for subcutaneous administration.</p><p>Patients with Renal Impairment: No formal trials were conducted to examine the effects of renal impairment on the pharmacokinetics of belimumab. BENLYSTA was studied in a limited number of adult patients with SLE who had mild (CrCl &sup3;60 and &lt;90&nbsp;mL/min), moderate (CrCl &sup3;30 and &lt;60&nbsp;mL/min), or severe (CrCl &sup3;15 and &lt;30&nbsp;mL/min) renal impairment: 770&nbsp;patients with mild renal impairment, 261&nbsp;patients with moderate renal impairment, and 14&nbsp;patients with severe renal impairment received belimumab intravenously; 121&nbsp;patients with mild renal impairment and 30&nbsp;patients with moderate renal impairment received belimumab subcutaneously. (See<em> Use in Specific Populations</em>).</p><p>Patients with Hepatic Impairment: No formal trials were conducted to examine the effects of hepatic impairment on the pharmacokinetics of belimumab. Baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels did not significantly influence belimumab pharmacokinetics. (See<em> Use in Specific Populations</em>).</p><p>Drug Interaction Studies</p><p>No formal drug interaction studies have been conducted with BENLYSTA. Concomitant use of mycophenolate, cyclophosphamide, azathioprine, methotrexate, antimalarials, NSAIDs, aspirin, and/or HMG-CoA reductase inhibitors did not significantly influence belimumab pharmacokinetics. Coadministration of steroids and angiotensin-converting enzyme (ACE) inhibitors resulted in an increase of systemic clearance of belimumab that was not clinically significant because the magnitude was well within the range of normal variability of clearance. The effect of belimumab on the pharmacokinetics of other drugs has not been evaluated.</p><p>Immunogenicity</p><p>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of BENLYSTA or of other belimumab products.</p><p>In Trials 2 and 3 (intravenous dosing in adults with SLE), anti-belimumab antibodies were assessed during the respective 52-week and 76-week, placebo-controlled periods and detected in 4 of 563 (0.7%) patients receiving BENLYSTA 10&nbsp;mg/kg and in 27 of 559 (4.8%) patients receiving BENLYSTA 1&nbsp;mg/kg. The reported frequency for the group receiving 10&nbsp;mg/kg may underestimate the actual frequency due to lower assay sensitivity in the presence of high drug concentrations. Neutralizing antibodies were detected in 3&nbsp;patients receiving BENLYSTA 1&nbsp;mg/kg. Three patients with anti-belimumab antibodies experienced mild infusion reactions of nausea, erythematous rash, pruritus, eyelid edema, headache, and dyspnea; none of the reactions were life-threatening. In Trial&nbsp;4 (intravenous dosing in adult Black patients), anti-belimumab antibodies were detected in 2 of 321 (0.6%) patients receiving BENLYSTA 10&nbsp;mg/kg during the 52-week, placebo-controlled period. In Trial&nbsp;5 (intravenous dosing in adults with lupus nephritis), there was no formation of anti-belimumab antibodies in 224 patients receiving BENLYSTA 10&nbsp;mg/kg plus standard therapy during the 104-week, placebo‑controlled period. In Trial&nbsp;6 (intravenous dosing in pediatric patients with SLE), there was no formation of anti-belimumab antibodies in 53 patients receiving BENLYSTA&nbsp;10&nbsp;mg/kg plus standard therapy during the 52-week, placebo‑controlled period. In Trial&nbsp;7 (subcutaneous dosing in adults with SLE), there was no formation of anti‑belimumab antibodies in 556 patients receiving BENLYSTA 200&nbsp;mg during the 52-week, placebo-controlled period.</p><p>The clinical relevance of the presence of anti-belimumab antibodies is not known.</p><p>CLINICAL STUDIES</p><p>The safety and effectiveness of BENLYSTA administered intravenously plus standard therapy were evaluated in 4 randomized, double‑blind, placebo‑controlled trials involving 2,581&nbsp;adult patients with SLE (Trial&nbsp;1, NCT 00071487, Trial&nbsp;2, NCT 00410384, Trial&nbsp;3, NCT 00424476, and Trial&nbsp;4 NCT 01632241), and one trial involving 93 pediatric patients (Trial&nbsp;6, NCT 01649765) with SLE according to the American College of Rheumatology criteria. In these trials, patients with severe active lupus nephritis and severe active CNS lupus were excluded. Patients were on a stable standard therapy SLE treatment regimen comprising any of the following (alone or in combination): corticosteroids, antimalarials, NSAIDs, and immunosuppressives. Use of other biologics and intravenous cyclophosphamide was not permitted.</p><p>In addition, the safety and effectiveness of BENLYSTA administered intravenously plus standard therapy was evaluated in a randomized, double‑blind, placebo‑controlled trial in 448 adult patients with active lupus nephritis (Trial&nbsp;5; NCT 01639339).</p><p>&nbsp;</p><p>1 Intravenous Administration in Adults with SLE</p><p>Trial&nbsp;1: SLE &ndash; BENLYSTA 1 mg/kg, 4 mg/kg, 10 mg/kg - Intravenous</p><p>Trial&nbsp;1 enrolled 449 patients and evaluated doses of 1, 4, and 10 mg/kg BENLYSTA plus standard therapy compared with placebo plus standard therapy over 52 weeks in patients with SLE. Patients had to have a Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of <u>&gt;</u>4 at baseline and a history of autoantibodies (anti-nuclear antibody [ANA] and/or anti-double-stranded DNA [anti-dsDNA]), but 28% of the population was autoantibody negative at baseline. The co-primary endpoints were percent change in SELENA-SLEDAI score at Week 24 and time to first flare over 52 weeks. No significant differences between any of the groups receiving BENLYSTA and the group receiving placebo were observed. Exploratory analysis of this trial identified a subgroup of patients (72%) who were autoantibody positive in whom BENLYSTA appeared to offer benefit. The results of this trial informed the design of Trials 2 and 3 and led to the selection of a target population and indication that is limited to autoantibody-positive SLE patients.</p><p>Trials 2, 3 and 4: SLE &ndash; BENLYSTA 1 mg/kg and 10 mg/kg - Intravenous</p><p>Trials 2 and 3 were randomized, double‑blind, placebo‑controlled trials in patients with SLE that were similar in design except duration; Trial&nbsp;2 (N&nbsp;=&nbsp;819) was 76 weeks&rsquo; duration and Trial&nbsp;3 (N&nbsp;=&nbsp;865) was 52 weeks&rsquo; duration. Patients had active SLE disease with a SELENA‑SLEDAI score &sup3;6 and positive autoantibody test results at screening. Patients were excluded from the trial if they had ever received treatment with a B‑cell-targeted agent or if they were currently receiving other biologic agents. Intravenous cyclophosphamide was not permitted within the previous 6 months or during the trial. Trial 2 was conducted primarily in North America and Europe. Trial&nbsp;3 was conducted in South America, Eastern Europe, Asia, and Australia.</p><p>Baseline concomitant medications included corticosteroids (Trial 2: 76%, Trial 3: 96%), immunosuppressives (Trial 2: 56%, Trial 3: 42%; including azathioprine, methotrexate, and mycophenolate), and antimalarials (Trial 2: 63%, Trial 3: 67%). Most patients (&gt;70%) were receiving 2 or more classes of SLE medications.</p><p>In Trial 2 and Trial 3, more than 50% of patients had 3 or more active organ systems involved at baseline. The most common active organ systems at baseline based on SELENA-SLEDAI were mucocutaneous (82% in both trials), immune (Trial 2: 74%, Trial 3: 85%), and musculoskeletal (Trial 2: 73%, Trial 3: 59%). Less than 16% of patients had some degree of renal activity and less than 7% of patients had activity in the vascular, cardio-respiratory, or CNS systems.</p><p>At screening, patients were stratified by disease severity based on their SELENA‑SLEDAI score (&le;9&nbsp;vs.&nbsp;&sup3;10), proteinuria level (&lt;2&nbsp;g/24&nbsp;h&nbsp;vs.&nbsp;&sup3;2&nbsp;g/24&nbsp;h), and race (African or Indigenous-American descent vs. other), and then randomly assigned to receive BENLYSTA 1&nbsp;mg/kg, BENLYSTA 10&nbsp;mg/kg, or placebo in addition to standard therapy. The patients were administered trial medication intravenously over a 1‑hour period on Days 0, 14, 28, and then every 28&nbsp;days for 48 weeks in Trial 3 and for 72&nbsp;weeks in Trial 2.</p><p>The primary efficacy endpoint was a composite endpoint (SLE Responder Index-4 or SRI-4) that defined response as meeting each of the following criteria at Week&nbsp;52 compared with baseline:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &sup3;4‑point reduction in the SELENA‑SLEDAI score, and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2&nbsp;new BILAG B organ domain scores, and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; no worsening (&lt;0.30‑point increase) in Physician&rsquo;s Global Assessment (PGA) score.</p><p>The SRI uses the SELENA‑SLEDAI score as an objective measure of reduction in global disease activity; the BILAG index to ensure no significant worsening in any specific organ system; and the PGA to ensure that improvements in disease activity are not accompanied by worsening of the patient&rsquo;s condition overall.</p><p>In both Trials 2 and 3, the proportion of patients with SLE achieving an SRI-4 response, as defined for the primary endpoint, was significantly higher in the group receiving BENLYSTA 10&nbsp;mg/kg plus standard therapy than in the group receiving placebo plus standard therapy. The effect on the SRI-4 was not consistently significantly different for patients receiving BENLYSTA 1&nbsp;mg/kg plus standard therapy relative to placebo plus standard therapy in both trials. The 1-mg/kg dose is not recommended. The trends in comparisons between the treatment groups for the rates of response for the individual components of the endpoint were generally consistent with that of the SRI-4 (Table 3). At Week 76 in Trial 2, the SRI-4 response rate with BENLYSTA 10&nbsp;mg/kg was not significantly different from that of placebo (39% and 32%, respectively).</p><p>Table 3. Clinical Response Rate in Patients with SLE after 52&nbsp;Weeks of Treatment</p><table border="1" cellspacing="0" cellpadding="0" style="width:672px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Response</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Trial&nbsp;2</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Trial&nbsp;3</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Placebo + Standard Therapy</strong></p><p><strong>(n&nbsp;=&nbsp;275)</strong></p></td><td style="vertical-align:bottom"><p><strong>BENLYSTA</strong><strong> </strong><strong>1 mg/kg + Standard </strong><strong>Therapy<sup>a</sup></strong></p><p><strong>(n = 271)</strong></p></td><td style="vertical-align:bottom"><p><strong>BENLYSTA</strong></p><p><strong>10&nbsp;mg/kg + Standard Therapy</strong></p><p><strong>(n&nbsp;=&nbsp;273)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo + </strong></p><p><strong>Standard Therapy</strong></p><p><strong>(n = 287)</strong></p></td><td style="vertical-align:bottom"><p><strong>BENLYSTA</strong></p><p><strong>1 mg/kg + Standard Therapy</strong><strong><sup>a</sup></strong></p><p><strong>(n = 288)</strong></p></td><td style="vertical-align:bottom"><p><strong>BENLYSTA</strong></p><p><strong>10&nbsp;mg/kg + Standard Therapy</strong></p><p><strong>(n&nbsp;=&nbsp;290)</strong></p></td></tr><tr><td style="vertical-align:top"><p>SLE Responder Index-4 (SRI-4)<sup>b</sup></p></td><td style="vertical-align:top"><p>34%</p></td><td style="vertical-align:top"><p>41%</p><p>&nbsp;</p><p><em>P</em>&nbsp;=&nbsp;0.104</p></td><td style="vertical-align:top"><p>43%</p><p>&nbsp;</p><p><em>P</em>&nbsp;=&nbsp;0.021</p></td><td style="vertical-align:top"><p>44%</p></td><td style="vertical-align:top"><p>51%</p><p>&nbsp;</p><p><em>P&nbsp;</em>=&nbsp;0.013</p></td><td style="vertical-align:top"><p>58%</p><p>&nbsp;</p><p><em>P</em>&nbsp;&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Odds Ratio</p><p>(95% CI) vs. placebo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.3</p><p>(0.9, 1.9)</p></td><td style="vertical-align:top"><p>1.5</p><p>(1.1, 2.2)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.6</p><p>(1.1, 2.2)</p></td><td style="vertical-align:top"><p>1.8</p><p>(1.3, 2.6)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>Components of SLE Responder Index-4 (SRI-4)</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients with reduction in SELENA-SLEDAI &sup3;4</p></td><td style="vertical-align:top"><p>36%</p></td><td style="vertical-align:top"><p>43%</p></td><td style="vertical-align:top"><p>47%</p></td><td style="vertical-align:top"><p>46%</p></td><td style="vertical-align:top"><p>53%</p></td><td style="vertical-align:top"><p>58%</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients with no worsening by BILAG index</p></td><td style="vertical-align:top"><p>65%</p></td><td style="vertical-align:top"><p>75%</p></td><td style="vertical-align:top"><p>69%</p></td><td style="vertical-align:top"><p>73%</p></td><td style="vertical-align:top"><p>79%</p></td><td style="vertical-align:top"><p>81%</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients with no worsening by PGA</p></td><td style="vertical-align:top"><p>63%</p></td><td style="vertical-align:top"><p>73%</p></td><td style="vertical-align:top"><p>69%</p></td><td style="vertical-align:top"><p>69%</p></td><td style="vertical-align:top"><p>79%</p></td><td style="vertical-align:top"><p>80%</p></td></tr></tbody></table><p><sup>a&nbsp; </sup>The 1-mg/kg dose is not recommended.</p><p><sup>b&nbsp; </sup>Patients dropping out of the trial early or experiencing certain increases in background medication were considered as failures in these analyses. In both trials, a higher proportion of placebo patients were considered as failures for this reason compared with the groups receiving BENLYSTA.</p><p>The reduction in disease activity seen in the SRI-4 was related primarily to improvement in the most commonly involved organ systems; namely, mucocutaneous, musculoskeletal, and immune.</p><p>Effect in Black/African-American Patients: In Trials&nbsp;2 and 3, exploratory sub-group analyses of SRI-4 response rate in Black patients (n&nbsp;=&nbsp;148) were performed. The SRI-4 response rate in Black patients in groups receiving BENLYSTA plus standard therapy was less than that in the group receiving placebo plus standard therapy (22/50 or 44% for placebo, 15/48 or 31% for BENLYSTA 1 mg/kg, and 18/50 or 36% for BENLYSTA 10 mg/kg).</p><p>Trial&nbsp;4 was a 2:1 randomized, placebo-controlled trial in Black patients with SLE (N&nbsp;=&nbsp;448) conducted in North America, South America, Europe, and Africa (same study design as Trials&nbsp;2 and 3 with exceptions of patients having a baseline SELENA-SLEDAI score of <u>&gt;</u>8 and using the modified SLEDAI-2K scoring for proteinuria). The population had a mean age of 39&nbsp;years (range: 18 to 71) and 97% were female. The proportion of Black patients achieving an SRI-S2K response at Week&nbsp;52 (primary endpoint), and the individual components of the endpoint, were higher in the group receiving BENLYSTA 10&nbsp;mg/kg plus standard therapy relative to the group receiving placebo plus standard therapy. However, the treatment difference was not statistically significant (Table 4).</p><p><strong>Table 4. Clinical Response Rate in Black Patients with SLE after 52&nbsp;Weeks of Treatment (Trial&nbsp;4)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:top"><p><strong>Response</strong><sup> a</sup></p></td><td style="vertical-align:top"><p><strong>Placebo </strong><strong>+</strong></p><p><strong>Standard Therapy</strong></p><p><strong>(n</strong>&nbsp;<strong>=</strong>&nbsp;<strong>149)</strong></p></td><td style="vertical-align:bottom"><p><strong>BENLYSTA</strong></p><p><strong>10 mg/kg </strong><strong>+</strong></p><p><strong>Standard Therapy</strong></p><p><strong>(n</strong>&nbsp;<strong>=</strong>&nbsp;<strong>298)</strong></p></td></tr><tr><td style="vertical-align:top"><p>SLE Responder Index (SRI-S2K)<sup>b</sup></p></td><td style="vertical-align:top"><p>42%</p></td><td style="vertical-align:top"><p>49%</p></td></tr><tr><td style="vertical-align:top"><p>Odds Ratio (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.4 (0.9, 2.1)</p><p><em>P&nbsp;</em>=&nbsp;0.107</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Components of SLE Responder Index (SRI-S2K)</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients with reduction in SELENA‑SLEDAI-S2K &sup3;4</p></td><td style="vertical-align:top"><p>42%</p></td><td style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>Odds Ratio (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.5 (1.0, 2.2)</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients with no worsening by BILAG index</p></td><td style="vertical-align:top"><p>62%</p></td><td style="vertical-align:top"><p>68%</p></td></tr><tr><td style="vertical-align:top"><p>Odds Ratio (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.2 (0.8, 1.9)</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients with no worsening by PGA</p></td><td style="vertical-align:top"><p>64%</p></td><td style="vertical-align:top"><p>70%</p></td></tr><tr><td style="vertical-align:top"><p>Odds Ratio (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.3 (0.8, 1.9)</p></td></tr></tbody></table><p><sup>a&nbsp; </sup>Analyses excluded any subject missing a baseline assessment for any of the components (1 for belimumab).</p><p><sup>b&nbsp; </sup>Patients dropping out of the trial early or experiencing certain increases in background medication were considered as failures in these analyses. A higher proportion of patients receiving placebo were considered as failures for this reason compared with the group receiving BENLYSTA.</p><p>Effect on Concomitant Steroid Treatment: In Trial 2 and Trial 3, 46% and 69% of patients, respectively, were receiving prednisone at doses &gt;7.5 mg/day at baseline. The proportion of patients able to reduce their average prednisone dose by at least 25% to &pound;7.5&nbsp;mg/day during Weeks&nbsp;40 through 52 was not consistently significantly different for BENLYSTA plus standard therapy relative to placebo plus standard therapy in both trials. In Trial 2, 17% of patients receiving BENLYSTA 10&nbsp;mg/kg plus standard therapy and 19% of patients receiving BENLYSTA 1&nbsp;mg/kg plus standard therapy achieved this level of steroid reduction compared with 13% of patients receiving placebo plus standard therapy. In Trial 3, 19%, 21%, and 12% of patients receiving BENLYSTA 10&nbsp;mg/kg, BENLYSTA 1&nbsp;mg/kg, and placebo, respectively, plus standard therapy achieved this level of steroid reduction.</p><p>Effect on Severe SLE Flares: The probability of experiencing a severe SLE flare, as defined by a modification of the SELENA Trial flare criteria, which excluded severe flares triggered only by an increase of the SELENA-SLEDAI score to &gt;12, was calculated for both Trials 2 and 3. The proportion of patients having at least 1 severe flare over 52 weeks was not consistently significantly different for BENLYSTA plus standard therapy relative to placebo plus standard therapy in both trials. In Trial 2, 18% of patients receiving BENLYSTA 10&nbsp;mg/kg plus standard therapy and 16% of patients receiving BENLYSTA 1&nbsp;mg/kg plus standard therapy had a severe flare compared with 24% of patients receiving placebo plus standard therapy. In Trial 3, 14%, 18%, and 23% of patients receiving BENLYSTA 10&nbsp;mg/kg, BENLYSTA 1&nbsp;mg/kg and placebo, respectively, plus standard therapy had a severe flare.</p><p>2. Intravenous Administration in Adults with Lupus Nephritis</p><p>Trial&nbsp;5: Lupus Nephritis &ndash; BENLYSTA 10 mg/kg - Intravenous</p><p>The safety and effectiveness of BENLYSTA 10&nbsp;mg/kg administered intravenously over 1 hour on Days 0, 14, 28, and then every 28&nbsp;days plus standard therapy were evaluated in a 104-week, randomized, double‑blind, placebo‑controlled trial in 448&nbsp;patients with active proliferative and/or membranous lupus nephritis (Trial&nbsp;5). The patients had a clinical diagnosis of SLE according to American College of Rheumatology classification criteria; biopsy-proven lupus nephritis Class III, IV, and/or V; and had active renal disease at screening requiring standard therapy: corticosteroids with 1) mycophenolate for induction followed by mycophenolate for maintenance, or 2) cyclophosphamide for induction followed by azathioprine for maintenance. This trial was conducted in Asia, North America, South America, and Europe. The mean age of patients was 33&nbsp;years (range: 18 to 77); the majority (88%) were female.</p><p>The primary efficacy endpoint was Primary Efficacy Renal Response (PERR) at Week&nbsp;104, defined as a response at Week&nbsp;100 confirmed by a repeat measurement at Week&nbsp;104 of the following parameters: urine protein:creatinine ratio (uPCR) &le;0.7&nbsp;g/g and estimated glomerular filtration rate (eGFR) &ge;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> or no decrease in eGFR of &gt;20% from pre-flare value.</p><p>The major secondary endpoints included:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete Renal Response (CRR) defined as a response at Week&nbsp;100 confirmed by a repeat measurement at Week&nbsp;104 of the following parameters: uPCR &lt;0.5&nbsp;g/g and eGFR &ge;90&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> or no decrease in eGFR of &gt;10% from pre-flare value.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PERR at Week&nbsp;52.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Time to renal-related event or death (renal-related event defined as first event of end-stage renal disease, doubling of serum creatinine, renal worsening [defined by quantified increase in proteinuria and/or impaired renal function], or receipt of renal disease-related prohibited therapy due to inadequate lupus nephritis control or renal flare management).</p><p>The proportion of patients achieving PERR at Week&nbsp;104 was significantly higher in patients receiving BENLYSTA plus standard therapy compared with placebo plus standard therapy (Table 5). The major secondary endpoints also showed significant improvement with BENLYSTA plus standard therapy compared with placebo plus standard therapy (Table 5 and Table 6).</p><p><strong>Table 5. Efficacy Results in Adults with Lupus Nephritis (Trial&nbsp;5)</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc485891195'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Toc485891195'><b> DOCVARIABLE
vault_nd_b1cf758d-1741-4699-be4f-00503a59839c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc485891195'></span><span style='mso-element:field-end'></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Efficacy Endpoint<sup>a</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo +</strong></p><p><strong>Standard Therapy</strong></p><p><strong>n&nbsp;=&nbsp;223</strong></p></td><td style="vertical-align:bottom"><p><strong>BENLYSTA +</strong></p><p><strong>Standard Therapy</strong></p><p><strong>n&nbsp;=&nbsp;223</strong></p></td><td style="vertical-align:bottom"><p><strong>Odds Ratio (OR) vs. Placebo</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Primary Efficacy Renal Response (PERR) at Week 104</strong><strong><sup>b,c</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Responders</p></td><td style="vertical-align:top"><p>32%</p></td><td style="vertical-align:top"><p>43%</p></td><td style="vertical-align:top"><p>1.6</p><p>(1.0, 2.3)</p><p><em>P&nbsp;=&nbsp;</em>0.031</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p>Components of PERR</p></td></tr><tr><td style="vertical-align:top"><p>Urine protein:creatinine ratio &le;0.7&nbsp;g/g</p></td><td style="vertical-align:top"><p>34%</p></td><td style="vertical-align:top"><p>44%</p></td><td style="vertical-align:top"><p>1.5</p><p>(1.0, 2.3)</p></td></tr><tr><td style="vertical-align:top"><p>eGFR &ge;60 mL/min/1.73&nbsp;m<sup>2</sup> or no decrease in eGFR from pre-flare value of &gt;20%</p></td><td style="vertical-align:top"><p>50%</p></td><td style="vertical-align:top"><p>57%</p></td><td style="vertical-align:top"><p>1.3</p><p>(0.9, 1.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Complete Renal Response (CRR) at Week 104</strong><strong><sup>b,c</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Responders</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>30%</p></td><td style="vertical-align:top"><p>1.7</p><p>(1.1, 2.7)</p><p><em>P&nbsp;=&nbsp;</em>0.017</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p>Components of CRR</p></td></tr><tr><td style="vertical-align:top"><p>Urine protein:creatinine ratio &lt;0.5&nbsp;g/g</p></td><td style="vertical-align:top"><p>29%</p></td><td style="vertical-align:top"><p>39%</p></td><td style="vertical-align:top"><p>1.6</p><p>(1.1, 2.4)</p></td></tr><tr><td style="vertical-align:top"><p>eGFR &ge;90 mL/min/1.73&nbsp;m<sup>2</sup> or no decrease in eGFR from pre-flare value of &gt;10%</p></td><td style="vertical-align:top"><p>40%</p></td><td style="vertical-align:top"><p>47%</p></td><td style="vertical-align:top"><p>1.3</p><p>(0.9, 2.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PERR at Week 52</strong><strong><sup>b</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Responders</p></td><td style="vertical-align:top"><p>35%</p></td><td style="vertical-align:top"><p>47%</p></td><td style="vertical-align:top"><p>1.6</p><p>(1.1, 2.4)</p><p><em>P&nbsp;=&nbsp;</em>0.025</p></td></tr></tbody></table><p>eGFR&nbsp;=&nbsp;Estimated glomerular filtration rate.</p><p><sup>a&nbsp; </sup>PERR at Week&nbsp;104 was the primary efficacy analysis; CRR at Week&nbsp;104 and PERR at Week&nbsp;52 were included in pre-specified testing hierarchy.</p><p><sup>b&nbsp; </sup>In order to be considered a responder, steroid treatment had to be reduced to &le;10&nbsp;mg/day from Week&nbsp;24. Patients who discontinued treatment early, received prohibited medication or increases in background standard therapy, or withdrew from the study were considered non-responders. Prohibited medications and increases in background standard therapy were defined as: 1) use of corticosteroids above that allowed by protocol; 2) additional immunosuppressive agents (except topicals) beyond their induction/maintenance regimens; 3) angiotensin converting enzyme inhibitors (ACE) inhibitors, angiotensin II receptor blockers (ARBs), or antimalarials initiated after Week&nbsp;24; 4) exceeding protocol-permitted doses for standard therapy (cyclophosphamide, azathioprine, mycophenolate); or 5) other biologics, IV immunoglobulin, or plasmapheresis.</p><p><sup>c&nbsp; </sup>The percentage of patients who did not take prohibited medications or have an increase in background standard therapy at Week&nbsp;104 was 83% for BENLYSTA and 74% for placebo.</p><p>In descriptive subgroup analyses, the PERR and CRR rates were examined by induction therapy (mycophenolate or cyclophosphamide), biopsy class (Class III or IV, Class III + V or Class IV + V, or Class V), and uPCR levels at baseline (&lt;3&nbsp;g/g or &ge;3&nbsp;g/g; post-hoc analysis) (Figure&nbsp;1).</p><p><strong>Figure&nbsp;1. Odds Ratio of PERR and CRR at Week&nbsp;104 across Subgroups<sup>a, b</sup> (Trial&nbsp;5)</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc485891195'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Toc485891195'><b> DOCVARIABLE
vault_nd_1107881b-f2ee-4ef1-93bb-260bc2bf59ca \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc485891195'></span><span style='mso-element:field-end'></span><![endif]--></p><p><sup>a&nbsp; </sup>Class III = Focal proliferative lupus nephritis; Class IV = Diffuse proliferative lupus nephritis; Class V = Membranous lupus nephritis; Class III + V = Mixed membranous-focal proliferative lupus nephritis; Class IV + V = Mixed membranous-diffuse proliferative lupus nephritis.</p><p><sup>b&nbsp; </sup>Baseline urine protein:creatinine ratio (uPCR) was a post-hoc analysis.</p><p>The proportion of responders for PERR by visit through Week&nbsp;104 is shown in Figure&nbsp;2.</p><p><strong>Figure&nbsp;2. </strong><strong>Primary Efficacy Renal Response </strong><strong>(PERR) in Adults with Lupus Nephritis (+/- Standard Error) by Visit<sup>a</sup> (Trial&nbsp;5)</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc485891195'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Toc485891195'><b> DOCVARIABLE
vault_nd_dc2eb927-224b-4773-bccb-263b1ec1b7fa \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc485891195'></span><span style='mso-element:field-end'></span><![endif]--></p><p><sup>a&nbsp; </sup>Analysis is descriptive; bars represent standard error. The same patients may not have responded at each timepoint.</p><p>In Trial&nbsp;5, subjects who received BENLYSTA were significantly less likely to experience a renal-related event or death compared with placebo (Table 6).</p><p><strong>Table 6. Time to Renal-Related Event or Death in Adults with Lupus Nephritis (Trial&nbsp;5)</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc485891195'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Toc485891195'><b> DOCVARIABLE
vault_nd_aa76e2e2-ae05-4fa4-8abe-cc2a72185043 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc485891195'></span><span style='mso-element:field-end'></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0" style="width:101%"><thead><tr><td style="vertical-align:top"><p><strong>Efficacy Endpoint</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo +</strong></p><p><strong>Standard Therapy</strong></p><p><strong>n&nbsp;=&nbsp;223</strong></p></td><td style="vertical-align:bottom"><p><strong>BENLYSTA +</strong></p><p><strong>Standard Therapy</strong></p><p><strong>n&nbsp;=&nbsp;223</strong></p></td><td style="vertical-align:bottom"><p><strong>Hazard Ratio (HR) vs. Placebo</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Time to Renal-Related Event or Death<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients with event<sup>b</sup></p><p>Number of patients with event</p></td><td style="vertical-align:top"><p>28%</p><p>63</p></td><td style="vertical-align:top"><p>16%</p><p>35</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Time to event<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.5</p><p>(0.3, 0.8)</p><p><em>P&nbsp;=&nbsp;</em>0.001</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Components of endpoint<sup>d</sup></p><p>Percentage of patients with event</p></td></tr><tr><td style="vertical-align:top"><p>End-stage renal disease (ESRD)</p></td><td style="vertical-align:top"><p>0.4%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Doubling of serum creatinine from baseline</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal worsening<sup>e</sup></p></td><td style="vertical-align:top"><p>18%</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal-related treatment failure<sup>f</sup></p></td><td style="vertical-align:top"><p>16%</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Death</p></td><td style="vertical-align:top"><p>1%</p></td><td style="vertical-align:top"><p>0.4%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a&nbsp; </sup>Time to renal-related event or death included in pre-specified testing hierarchy.</p><p><sup>b&nbsp; </sup>When excluding deaths from analysis (1 for BENLYSTA; 2 for placebo), the percentage of patients with a renal-related event was 15% for BENLYSTA compared with 27% for placebo (HR&nbsp;=&nbsp;0.5; 95%&nbsp;CI: 0.3, 0.8).</p><p><sup>c&nbsp; </sup>Subjects who discontinued treatment, were withdrawn from the study, lost to follow-up, or had a treatment failure not related to renal disease were censored on the date of the event. Subjects who completed the 104-week treatment period were censored at the Week&nbsp;104 visit. Time to event was defined as (event date minus treatment start date plus 1 day).</p><p><sup>d </sup>Patients could have had more than one event; the first event contributed to the overall endpoint.</p><p><sup>e&nbsp; </sup>Renal worsening was prospectively defined as the development of increased proteinuria and/or impaired renal function defined as: 1) Increased proteinuria (using spot urine): a reproducible increase in 24-hour urine protein levels to &gt;1&nbsp;g/g if the baseline value was &lt;0.2&nbsp;g/g or &gt;2&nbsp;g/g if the baseline value was between 0.2&nbsp;g/g and 1&nbsp;g/g or more than twice the value at baseline if the baseline value was &gt;1&nbsp;g/g; and 2) Impaired renal function: a reproducible decrease in eGFR of &gt;20% accompanied by at least 1 of the following: proteinuria (&gt;1&nbsp;g/g), red blood cell casts, or white blood cell casts.</p><p><sup>f&nbsp; </sup>Renal-related treatment failure was prospectively defined as intake of prohibited medications for adjudicated inadequate lupus nephritis control or renal flare management.</p><p>In descriptive subgroup analyses of time to renal-related event or death, results were consistent with the overall endpoint regardless of induction therapy (mycophenolate or cyclophosphamide), biopsy class (Class III or IV, Class III + V or Class IV + V, or Class V; post-hoc analysis), and baseline proteinuria (&lt;3&nbsp;g/g or &ge;3&nbsp;g/g; post-hoc analysis). The treatment difference was primarily driven by the renal worsening and renal-related treatment failure components of the endpoint.</p><p>3. Intravenous Administration in Pediatric Patients with SLE</p><p>Trial&nbsp;6: SLE &ndash; BENLYSTA 10 mg/kg in Pediatric Patients - Intravenous</p><p>The safety and efficacy of BENLYSTA was evaluated in an international, randomized, double-blind, placebo‑controlled, 52-week, pharmacokinetics (PK), efficacy and safety study conducted in 93 pediatric patients with a clinical diagnosis of SLE according to the American College of Rheumatology classification criteria. Patients had active SLE disease, defined as a SELENA-SLEDAI score &ge;6 and positive autoantibodies at screening as defined in the adult trials. Patients were on a stable SLE treatment regimen (standard of care) and had similar inclusion and exclusion criteria as in the adult studies. The median age was 15&nbsp;years (range: 6 to 17). The majority (95%) of patients were female. More than 50% of patients had 3 or more active organ systems involved at baseline. The most common active organ systems at baseline based on SELENA-SLEDAI were mucocutaneous (91%), immunologic (74%), and musculoskeletal (73%). Overall, 19% of pediatric patients had some degree of renal activity and less than 7% had activity in the cardio-respiratory, hematologic, CNS or vascular systems. Randomization into age-related treatment cohorts was stratified by screening SELENA-SLEDAI scores (6 to 12 vs &gt;13) and age (5 to 11&nbsp;years vs 12 to 17&nbsp;years).</p><p>The primary efficacy endpoint was the SLE Responder Index (SRI-4) at Week&nbsp;52, as described in the adult intravenous trials. There was a numerically higher proportion of pediatric patients achieving a response in SRI‑4 and its components in pediatric patients receiving BENLYSTA plus standard therapy compared with placebo plus standard therapy (Table 7).</p><p><strong>Table 7. Pediatric Response Rate at Week 52<sup>a</sup> (Trial&nbsp;6)</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc485891195'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Toc485891195'><b> DOCVARIABLE
vault_nd_0a9c5add-698c-42df-bfb9-3ab0da225a6f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></b></span><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc485891195'></span><span style='mso-element:field-end'></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0" style="width:636px"><tbody><tr><td style="vertical-align:top"><p><strong>Response<sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>Placebo +</strong></p><p><strong>Standard Therapy</strong></p><p><strong>(n&nbsp;=&nbsp;39)</strong></p></td><td style="vertical-align:bottom"><p><strong>BENLYSTA</strong></p><p><strong>10 mg/kg +</strong></p><p><strong>Standard Therapy</strong></p><p><strong>(n&nbsp;=&nbsp;53)</strong></p></td></tr><tr><td style="vertical-align:top"><p>SLE Responder Index</p></td><td style="vertical-align:top"><p>44%</p></td><td style="vertical-align:top"><p>53%</p></td></tr><tr><td style="vertical-align:top"><p>Odds Ratio</p><p>(95% CI) vs. Placebo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.49</p><p>(0.64, 3.46)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Components of SLE Responder Index</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients with reduction in SELENA‑SLEDAI &sup3;4</p></td><td style="vertical-align:top"><p>44%</p></td><td style="vertical-align:top"><p>55%</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients with no worsening by BILAG index</p></td><td style="vertical-align:top"><p>62%</p></td><td style="vertical-align:top"><p>74%</p></td></tr><tr><td style="vertical-align:top"><p>Percent of patients with no worsening by PGA</p></td><td style="vertical-align:top"><p>67%</p></td><td style="vertical-align:top"><p>76%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Other endpoints</p></td></tr><tr><td style="vertical-align:top"><p>SRI-6 using SELENA SLEDAI &ge;6-point reduction</p></td><td style="vertical-align:top"><p>34%</p></td><td style="vertical-align:top"><p>41%</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients with a sustained SRI response</p></td><td style="vertical-align:top"><p>41%</p></td><td style="vertical-align:top"><p>43%</p></td></tr></tbody></table><p><sup>a&nbsp; </sup>Based on a non-powered trial.</p><p><sup>b&nbsp; </sup>Analyses excluded any subject missing a baseline assessment for any of the components (1 for placebo).</p><p>Effect on Concomitant Steroid Treatment: At baseline, 95% of pediatric patients were receiving prednisone. Among those pediatric patients, 20% of pediatric patients receiving BENLYSTA plus standard therapy reduced their average prednisone dose by at least 25% per day during Weeks&nbsp;44 through 52 compared with 21% of pediatric patients on placebo plus standard therapy.</p><p>Effect on Severe SLE Flares<em>:</em> In Trial&nbsp;6, the probability of experiencing a severe SLE flare, as measured by the modified SELENA-SLEDAI Flare Index, excluding severe flares triggered only by an increase of the SELENA-SLEDAI score to &gt;12, was calculated. The proportion of pediatric patients reporting at least one severe flare during the study was numerically lower in pediatric patients receiving BENLYSTA plus standard therapy (17%) compared with those receiving placebo plus standard therapy (35%). Pediatric patients receiving BENLYSTA 10 mg/kg plus standard therapy had a 64% lower risk of experiencing a severe flare during the 52 weeks of observation, relative to the placebo plus standard therapy group. Of the pediatric patients experiencing a severe flare, the median time to the first severe flare was 150 days in pediatric patients receiving BENLYSTA plus standard therapy compared with 113 days in pediatric patients receiving placebo plus standard therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p>Long-term animal studies have not been performed to evaluate the carcinogenic potential of belimumab.</p><p>Effects on male and female fertility have not been directly evaluated in animal studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric acid monohydrate</p><p>Sodium citrate dihydrate</p><p>Sucrose</p><p>Polysorbate 80</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>BENLYSTA</em> is not compatible with 5% dextrose.</p><p><em>BENLYSTA</em> must be prepared and administered only as directed, see <em>Special precautions for disposal and other handling.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Unopened vials</u></p><p>Store at between 2&deg;C and 8&deg;C.</p><p>Do not freeze.</p><p>Protect from light. Store in the original carton until use.</p><p><u>Reconstituted solution</u></p><p>After reconstitution with Water for Injections, and dilution in 0.9% sodium chloride (normal saline), 0.45% sodium chloride (half normal saline), or Lactated Ringer&rsquo;s solution, the product is stable for up to 8 hours at 2&deg;C to 8&deg;C or at room temperature. Protect from direct sunlight.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5&nbsp;mL Type 1 glass vial sealed with a latex-free siliconised rubber stopper and a flip-off seal containing 120&nbsp;mg <em>BENLYSTA</em> as a lyophylised powder.&nbsp;</p><p>20&nbsp;mL Type 1 glass vial sealed with a latex-free siliconised<strong> </strong>rubber stopper and a flip-off seal containing 400&nbsp;mg <em>BENLYSTA</em> as a lyophylised powder.&nbsp;</p><p>The drug is supplied in a single use vial without a preservative.&nbsp;</p><p><em>BENLYSTA is not compatible with 5% dextrose.</em></p><p><em>Belimumab lyophilised powder for intravenous infusion must be prepared and administered only as directed, see Special precautions for disposal and other handling.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Reconstitution and dilution</strong></p><p><em>BENLYSTA</em> does not contain a preservative; therefore, reconstitution and dilution must be carried out under aseptic conditions.</p><p>Allow 10 to 15 minutes for the vial to warm to room temperature.</p><p>It is recommended that a 21-25 gauge needle be used when piercing the vial stopper for reconstitution and dilution.</p><p>&nbsp;</p><p>The 120&nbsp;mg single-use vial of <em>BENLYSTA</em> should be reconstituted with 1.5 mL of sterile Water for Injections to yield a final concentration of 80&nbsp;mg/mL belimumab. The 400&nbsp;mg single-use vial of <em>BENLYSTA</em> should be reconstituted with 4.8&nbsp;mL of sterile Water for Injections to yield a final concentration of 80&nbsp;mg/mL belimumab.</p><p>The stream of sterile water should be directed toward the side of the vial to minimise foaming. Gently swirl the vial for 60&nbsp;seconds. Allow the vial to sit at room temperature during reconstitution, gently swirling the vial for 60&nbsp;seconds every five minutes until the powder is dissolved. Do not shake.</p><p>Reconstitution is typically complete within 10 to 15&nbsp;minutes after the sterile water has been added, but it may take up to 30&nbsp;minutes. Protect the reconstituted solution from direct sunlight.</p><p>If a mechanical reconstitution device is used to reconstitute <em>BENLYSTA</em> it should not exceed 500&nbsp;rpm and the vial should be swirled for no longer than 30&nbsp;minutes.</p><p>Once reconstitution is complete, the solution should be opalescent and colourless to pale yellow, and without particles. Small air bubbles, however, are expected and acceptable.</p><p>The reconstituted product is diluted to 250&nbsp;mL with 0.9% sodium chloride (normal saline), 0.45% sodium chloride (half normal saline) or Lactated Ringer&rsquo;s solution for intravenous infusion. For patients whose body weight is less than or equal to 40 kg, infusion bags with 100 mL normal saline, half normal saline or Lactated Ringer&rsquo;s solution may be considered providing that the resulting belimumab concentration in the infusion bag does not exceed 4 mg/mL.</p><p>5% Dextrose intravenous solutions are incompatible with <em>BENLYSTA</em> and should not be used.&nbsp;</p><p>From a 250&nbsp;mL (or 100&nbsp;mL) infusion bag or bottle of normal saline, half normal saline, or Lactated Ringer&rsquo;s solution, withdraw and discard a volume equal to the volume of the reconstituted <em>BENLYSTA</em> solution required for the patient&rsquo;s dose. Then add the required volume of the reconstituted <em>BENLYSTA</em> solution into the infusion bag or bottle. Gently invert the bag or bottle to mix the solution. Any unused solution in the vials must be discarded.</p><p>Inspect the <em>BENLYSTA</em> solution visually for particulate matter and discoloration prior to administration. Discard the solution if any particulate matter or discoloration is observed.</p><p>The reconstituted solution, if not used immediately, should be protected from direct sunlight and stored refrigerated at 2&deg;C to 8&deg;C.&nbsp; Solutions diluted in normal saline, half normal saline, or Lactated Ringer&rsquo;s solution may be stored at 2&deg;C to 8&deg;C or room temperature.</p><p>The total time from reconstitution of <em>BENLYSTA</em> to completion of infusion should not Exceed eight&nbsp;hours.</p><p><strong>Administration</strong></p><p><em>BENLYSTA</em> should be infused over a 1-hour period.</p><p><em>BENLYSTA</em> should not be infused concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of <em>BENLYSTA</em> with other agents.</p><p>No incompatibilities between <em>BENLYSTA</em> and polyvinylchloride or polyolefin bags</p><p>have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia
*member of the GlaxoSmithKline group of companies

MANUFACTURED BY: 
GlaxoSmithKline Manufacturing S.p.A*, Parma, Italy 
And 
Hospira, Inc. 1776 North Centennial Drive, McPherson, Kansas, USA 
Packed by: GlaxoSmithKline Manufacturing S.p.A*, Parma, Italy 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number:  US version 2/2023
Date of text approval:  15 February 2023

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>